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     Endocannabinoids (eCBs) are important mediators of synaptic plasticity, acting as 
retrograde messengers because they are released on demand from postsynaptic sites 
and activate presynaptic type I cannabinoid (CB1) receptors to suppress neurotransmitter 
release at both excitatory and inhibitory synapses. Similarly, brain derived neurotrophic 
factor (BDNF) is also a potent neuromodulator of synaptic transmission. The effect of 
BDNF on synaptic transmission is mediated by tropomyosin receptor kinase B (trkB) 
receptors. Both CB1 and trkB receptors are highly expressed at synapses throughout the 
neocortex and hippocampus. There is a growing evidence of cross talk between eCB and 
BDNF signaling. In particular, studies in our lab have shown that BDNF can trigger the 
release of endogenous endocannabinoids via phospholipase C signaling at inhibitory 
synapses in somatosensory cortex. It is not known whether BDNF-induced eCB release 
also occurs at excitatory synapses and in regions other than the neocortex. In the present 
studies, we examined a potential crosstalk between BDNF and eCB release at excitatory 
synapses in neocortex and inhibitory synapses in the hippocampus.  
 
     Using whole cell patch clamp recordings and pharmacological manipulations in mouse 
brain slices, we found at layer 5 excitatory synapses of somatosensory cortex, BDNF by 
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itself had little effect on spontaneous excitatory activity. However, blocking CB1 receptors 
or disrupting eCB release unmasked a significant BDNF-induced increase in the 
frequency of spontaneous excitatory synaptic events. These results suggest that BDNF 
induces the release of endogenous eCBs at these synapses that has a mitigating effect 
on the direct presynaptic effects of BDNF.  We also found evidence for BDNF-induced 
eCB release at inhibitory synapses in hippocampus.  Acute application of BDNF reduced 
spontaneous inhibitory synaptic activity in CA1 pyramidal neurons and this effect of BDNF 
was triggered by postsynaptic trkB activation. The suppressive effect of BDNF was 
mediated by eCB signaling because it was completely prevented by either blocking CB1 
receptors or by inhibiting eCB release. Further, we identified 2-AG as the specific eCB 
released by BDNF because blocking the synthesis of 2-AG prevented the effect of BDNF, 
whereas blocking 2-AG degradation enhanced the effect of BDNF. Collectively, these 
results suggest that in the hippocampus, BDNF-trkB signaling induces the release of the 
endogenous cannabinoid 2-AG, which acts as a retrograde messenger at presynaptic 
CB1 receptors to suppress GABA release. Taken together, these studies indicate that 
BDNF induces the release of eCBs at both inhibitory and excitatory synapses in 
neocortex, and the effects of BDNF at inhibitory synapses extend to the hippocampus. 
These studies contribute to the understanding of the physiological roles of BDNF and 
eCB signaling in the context of synaptic plasticity.  
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Chapter 1 
Introduction, Background and Rationale 
1.1 Overview 
     The most fascinating property of the brain is its plasticity – the ability to change 
throughout life as a result of experiences. Experience, whether it is a stressful event, 
recovery after injury, or learning in class, causes the brain to adapt, refine and modify 
neural activity and the organization of neural circuits. The most important and well-studied 
mechanism by which neural activity modifies brain function is synaptic plasticity. Synaptic 
plasticity is integral for learning and memory in both the developing and adult mammalian 
brain. Synaptic plasticity is embodied in Hebb’s postulate: “cells that fire together wire 
together”. It specifically refers to activity-dependent modulation that can potentiate or 
depress synaptic strength in a time frame lasting hours to days and sometimes even 
longer (Citri and Malenka, 2008). The cerebral cortex and hippocampus are two brain 
regions where extensive studies have been conducted to study and understand the 
mechanisms of synaptic plasticity. The cerebral cortex is composed of six distinct layers 
of synaptically-connected cells. The cortex controls sensory and motor perceptions along 
with higher cognitive tasks. Local circuitry exists in the cortex that integrates and transmits 
information received across all layers thereby shaping synaptic plasticity (Bannister, 
2005). On the other hand, the hippocampus is important for spatial and non-spatial forms 
of declarative memory. Different cortico-hippocampal circuits exist that transmit 
information to other brain regions. Hippocampal regions encode information pertaining to 
long term memory which is again heavily dependent on synaptic plasticity (Basu and 
Siegelbaum, 2015; Basu et al., 2013).   
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     Synaptic plasticity plays a key role in the formation and maturation of synaptic 
connectivity in the developing nervous system.  Synaptic plasticity is a complex process 
that involves multiple synaptic structures and numerous molecular mechanisms that are 
required for the formation and maintenance of a functional neuronal circuit. Synaptic 
plasticity occurs at both developmental and adult stages (Chaudhury et al., 2016).  Both 
excitatory synapses and inhibitory synapses exhibit this phenomenon.  In a typical CA1 
neuron, ~30,000 glutamatergic synaptic inputs and ~1700 GABAergic inputs are spread 
throughout the dendritic tree.  The excitatory neurotransmitter glutamate and the inhibitory 
neurotransmitter GABA are the primary mediators of “fast” synaptic transmission, 
however their effects are regulated by neuromodulators such as neurotrophins, 
endocannabinoids and neuropeptides (Basu and Siegelbaum, 2015; Basu et al., 2013).  
In particular, endocannabinoids (eCBs) and brain-derived neurotrophic factor (BDNF) 
have been identified as important modulators of synaptic plasticity. Though these two 
systems have been studied extensively in the context of synaptic plasticity, the 
interdependence between these systems is relatively unexplored.  The proposed studies 
will (1) explore potential interactions between BDNF and eCBs in neocortex and its 
functional relevance in the context of long-term synaptic plasticity and (2) examine the 
role of BDNF and eCBs in the hippocampus.  
 
1.2 The endogenous cannabinoid system 
     The endocannabinoid system is comprised of cannabinoid receptors, endogenous 
ligands, transporters, and enzymes required for ligand biosynthesis and degradation. 
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Each component is described in detail below.  The physiological role of the 
endocannabinoid system is described in section 1.3. 
 
1.2.1 Cannabinoid receptors 
     Two distinct cannabinoid receptors have been identified, type 1 and type 2 
cannabinoid receptors (CB1R and CB2R), both of which are Gi/o linked G-protein coupled 
receptors (GPCRs). While CB1Rs are highly expressed in the brain (Howlett et al., 2002), 
CB2Rs are predominantly expressed in the immune system. More recent studies have 
shown that CB2 is also present in both glia and neuronal processes in different brain 
regions, including cerebral cortex, hippocampus, amygdala, and striatum (Gong et al., 
2006; Van Sickle et al., 2005). Recent studies have also suggested that chronic activation 
of CB2R enhances excitatory synaptic transmission but has no acute effect on synaptic 
transmission (Kim and Li, 2015). CB2R knockouts shows impairments in excitatory 
synaptic transmission, long-term potentiation, and dendritic spine density in hippocampus 
(Li and Kim, 2016; Stempel et al., 2016). In the present studies, I will focus on CB1Rs 
and their function in synaptic plasticity as CB1R is the predominant cannabinoid receptor 
expressed in neurons. 
 
     The CB1R is one of the most highly expressed GPCR receptors in brain (Howlett, 
1998; Howlett et al., 2002), found in hippocampus, cerebral cortex, cerebellum, basal 
ganglia and nucleus accumbens (Egertova et al., 2003; Herkenham et al., 1990; Matsuda 
et al., 1993). CB1Rs are localized predominantly at presynaptic axonal terminals of both 
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GABAergic and glutamatergic cells (Katona et al., 1999; Katona et al., 2006). The main 
physiological effect of CB1R activation is to suppress presynaptic neurotransmitter 
release (Kreitzer and Regehr, 2001; Wilson et al., 2001; Wilson and Nicoll, 2001). The 
presynaptic localization of CB1Rs allows endocannabinoids to act as retrograde synaptic 
signals (Alger, 2002).  Activation of CB1R negatively regulates N- type and P/Q-type 
voltage gated calcium channels (VGCCs) (Mackie et al., 1995; Twitchell et al., 1997). 
Further, activation of CB1R also can lead to suppression of adenylyl cyclase and cAMP 
production as well as modulation of D- and M-type potassium channels (Mu et al., 1999; 
Schweitzer, 2000).  
 
     CB1R expression in the cortex displays a cell type-specific and laminar-specific 
pattern. High levels of CB1R expression have been reported in terminal and preterminal 
axons of cholecystokinin (CCK)-containing and calbindin-positive interneurons that 
surround pyramidal neurons (Bodor et al., 2005; Eggan and Lewis, 2007; Harkany et al., 
2005; Marsicano and Lutz, 1999). CCK cells are basket cells that innervate the 
perisomatic pyramidal neuron area (Neu et al., 2007) while calbindin-positive 
interneurons can be found in distal dendrites of pyramidal neurons in the cortex (DeFelipe 
et al., 1989; Wedzony and Chocyk, 2009). Higher amounts of CB1Rs are found at 
excitatory terminals compared to inhibitory terminals. CB1Rs are not detected in 
parvalbumin-, somatostatin-, or vasoactive intestinal peptide-containing interneurons in 
the cortex (Bodor et al., 2005; Marsicano and Lutz, 1999).  The lamina-specific pattern of 
CB1R in neocortex in rodents is characterized by high levels of expression in layers 2/3, 
5a, and 6 (Deshmukh et al., 2007; Egertova et al., 2003; Egertova and Elphick, 2000; 
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Marsicano and Lutz, 1999; Tsou et al., 1998). In contrary, in the prefrontal cortex of 
monkeys, CB1R is highly expressed in layer 4 (Eggan and Lewis, 2007). This differential 
distribution of CB1R across cortical layers and across species is an important factor in 
understanding the role of eCBs in synaptic plasticity and cortical function.  
 
     In addition to the classical cannabinoid receptors, two other related receptors, 
transient receptor potential vanilloid type- 1 ion channel (TRPV1) and GPR55 receptor 
also engage in eCB signaling. TRPV1 is a non-selective cation channel expressed in 
peripheral sensory neurons and its activation regulates synaptic transmission related to 
pain sensation (De Petrocellis et al., 2000).  Anandamide (AEA) is an endogenous 
cannabinoid ligand that acts as a full agonist at TRPV1 channels indicating a crosstalk 
between the endovanilloid and eCB systems.  However, it is not known if TRPV1 can 
modulate excitatory or inhibitory synaptic activity (Maccarrone et al., 2008; Ryberg et al., 
2007).  On the other hand, GPR55 is an orphan GPCR that has been recognized as a 
novel cannabinoid receptor. GPR55 can be activated by several ligands including THC, 
CP55, 940 but not by WIN55,212-2, a synthetic CB1 agonist. The function of GPR55 is 
currently unknown (Ryberg et al., 2007).  
 
1.2.2 Endogenous ligands in the brain and their synthesis 
     Endogenous ligands are the lipid molecules that are synthesized in brain and bind to 
CB1 receptors. There are several endogenous ligands, 2-arachidonoylglcyerol (2-AG), 
anandamide (AEA), noladin ether (Hanus et al., 2001), virodhamine (Porter et al., 2002) 
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and oleamide (Leggett et al., 2004). The two best-characterized ligands are 2-AG and 
AEA. Unlike typical neurotransmitters, eCBs are not packaged and stored in vesicles 
before release. Instead, they are synthesized and released ‘on-demand’ from membrane 
lipid precursors.  
 
     N-arachidonylethanolamide, derived from arachidonic acid in the plasma membrane, 
was the first identified eCB and was isolated from pig brain (Devane et al., 1992). Based 
on the euphoria associated with marijuana use and CB1 activation, N-
arachidonylethanolamide was named ‘anandamide’ meaning bliss in Sanskrit. AEA acts 
as a partial agonist for both CB1 and CB2Rs and full agonist for TPRV1 receptors (Ross 
et al., 2001; Starowicz et al., 2007). Multiple pathways exist for the production of 
anandamide. Three well known pathways will be described here: (1) the precursor of N-
arachidonyl phosphatidylethanolamine (NArPE) is synthesized in a Ca2+-dependent 
manner by the enzyme N-acyl transferase (NAT). NArPE is cleaved to AEA and 
phosphatidic acid through the action of NArPE specific phospholipase D (Di Marzo et al., 
1994). (2) phospholipase C-mediated hydrolysis of NAPE yields phosphoanandamide (p-
AEA) (Liu et al., 2008). This p-AEA is dephosphorylated to yield AEA. (3) Deacylation of 
NAPE by α,β-hydrolase 4 (Abhd4) and the subsequent cleavage of glycerophosphate 
yields anandamide (Liu et al., 2008).  
 
     2-AG is a full agonist of CB1R and CB2R and the concentration of 2-AG is higher than 
that of AEA in brain tissue (Stella et al., 1997; Sugiura et al., 1995). The major synthesis 
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pathway of 2-AG involves hydrolysis of phosphatidylinositol by phospholipase C (PLC) 
and subsequent hydrolysis of 1,2 – diacylglycerol (DAG) by a DAG lipase (DAGL) (Stella 
et al., 1997). Two isoforms of DAGL have been identified: DGLα and DGLβ (Bisogno et 
al., 2003). DGLα is related to 2-AG synthesis and release (Kano et al., 2009). 
Alternatively, DAG can be synthesized from phospholipase A2 or D from phosphatidic 
acid (Nakane et al., 2002). 2-AG and AEA are synthesized via different lipid metabolism 
pathways and mediate different functions upon activation of CB1Rs and CB2Rs (Piomelli, 
2003; Piomelli et al., 1998). 
 
1.2.3 Endocannabinoid mobilization and metabolism 
      The synthesized ligands are released in a non-vesicular manner and travel 
retrogradely to activate presynaptic CB1Rs. Several mechanisms have been known to 
induce eCB release. (1) Calcium-induced eCB release is driven by postsynaptic 
depolarization of the cell resulting in increase of intracellular Ca2+ via VGCCs (Pitler and 
Alger, 1992) and NMDA receptors (Ohno-Shosaku et al., 2007). Ca2+-ER is independent 
of PLC signaling, because PLC inhibitors failed to disrupt depolarization-induced eCB 
release in hippocampus and cerebellum (Chevaleyre and Castillo, 2003; Edwards et al., 
2012; Engler et al., 2006). Genetic ablations of various isoforms of PLC also did not alter 
eCB-mediated short term depression (Hashimotodani et al., 2008; Hashimotodani et al., 
2005; Maejima et al., 2005). (2) Receptor-driven eCB release (RER): Activation of group 
1 metabotropic receptor glutamate receptors (mGluR1) (Maejima et al., 2001), M1/M3 
muscarinic acetylcholine receptors (Kim et al., 2002; Straiker and Mackie, 2007), or orexin 
receptors (Haj-Dahmane and Shen, 2005) can activate PLCβ. This activation can lead to 
                                                                                         
8 
 
eCB release that is independent of postsynaptic Ca2+ elevation (Hashimotodani et al., 
2007b; Maejima et al., 2001). (3) Ca2+-assisted RER: In certain cases, combination of 
increased intracellular Ca2+ along with RER can induce eCB release. Calcium entry 
through postsynaptic depolarization in combination with mGluR or muscarinic agonists 
such as carbamylcholine or dihydroxyphenylglcyine (DHPG) can enhance eCB release 
(Martin and Alger, 1999; Ohno-Shosaku et al., 2002; Straiker and Mackie, 2007). (4) 
BDNF-induced release of eCBs, which requires BDNF, TrkB signaling, PLC Ɣ signaling 
and elevated intracellular Ca2+ (Lemtiri-Chlieh and Levine, 2010; Zhao and Levine, 2014). 
Each of these forms of eCB release share similarities yet have distinct mechanisms.  
 
     After release from the postsynaptic cell and activation of CB1 receptors, both AEA and 
2-AG are rapidly degraded by specific intracellular hydrolyzing enzymes. AEA is 
degraded into arachidonic acid and ethanolamine by fatty acid amide hydrolase (FAAH). 
FAAH is mostly expressed in postsynaptic membranes (Cravatt et al., 1996; Hillard et al., 
1995; Schmid et al., 1985). On the other hand, 2-AG is degraded by MAGL into glycerol 
and fatty acid. MAGL is located in the presynaptic terminals (Dinh et al., 2002). FAAH 
(Goparaju et al., 1998) and ABHD6 (Blankman et al., 2007) can also degrade 2-AG, 
however, the majority of 2-AG is degraded by MAGL. It is still unclear how eCBs are 
transported in and out of the membrane for release and reuptake processes. It has been 
proposed that the reuptake process involves carrier-mediated transport into cells and 
subsequent intracellular hydrolysis, however the identification and cloning of the 
transporter protein is still lacking (reviewed in (Piomelli, 2003)).  Another thought is that, 
rather than a typical transporter, fatty acid binding proteins (FABPs) are possible 
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intracellular AEA carriers that can transport AEA across the membrane. FABPs are 
expressed in the central nervous system and can help the movement of fatty acids freely 
inside the cells providing a rapid substrate delivery system of AEA to FAAH (Elmes et al., 
2015; Kaczocha et al., 2009).  
 
1.3 Endocannabinoid-mediated synaptic plasticity 
       eCBs acutely suppress inhibitory and excitatory neurotransmission in several brain 
regions as well as mediate several forms of short- and long- term depression at both 
excitatory and inhibitory synapses. 
 
1.3.1 Endocannabinoid-mediated short-term plasticity 
      Endocannabinoid-mediated short-term depression (eCB-STD) includes 
depolarization-induced suppression of inhibition (DSI) and excitation (DSE). eCB-
mediated DSI was first demonstrated at GABAergic synapses in CA1 pyramidal cells of 
hippocampus and cerebellum (Kreitzer and Regehr, 2001; Pitler and Alger, 1992; Wilson 
and Nicoll, 2001). Thereafter, eCB-mediated DSE at glutamatergic synapses was 
reported in the cerebellum and hippocampus (Kreitzer and Regehr, 2001). In neocortex, 
DSI was first reported by our group in layer 2/3 auditory and visual cortex (Trettel and 
Levine, 2003). Later studies reported DSI/DSE in amygdala (Zhu and Lovinger, 2005), 
basal ganglia (Hashimotodani et al., 2013), ventral tegmental area (Melis et al., 2004) 
and hypothalamus (Jo et al., 2005).  
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         In DSE/DSI, in response to postsynaptic depolarization-induced calcium influx, 
eCBs are released from postsynaptic sites and act retrogradely via CB1Rs to suppress 
neurotransmitter release. The suppression is very transient, lasting 2 to 3 minutes (Wilson 
and Nicoll, 2001). The critical step for releasing eCBs is a rise in intracellular calcium 
levels in the postsynaptic sites which can happen in few different ways: (a) via voltage 
gated calcium channels (VGCC) (Kreitzer and Regehr, 2001; Pitler and Alger, 1992; 
Wilson and Nicoll, 2001), (b) group I metabotropic receptors (mGluRs) and (c) muscarinic 
acetylcholine receptors, which mobilize stored calcium via phospholipase C (PLC) 
(reviewed in (Xu and Chen, 2015)). Elevation of intracellular Ca2+ induces STD while 
decrease of Ca2+ blocks STD. The transient suppression is believed to be mediated by 
direct βƔ subunit of Gi/o protein interacting with N-type and P/Q-type voltage gated 
calcium channels leading to a rapid suppression of presynaptic Ca2+ influx (Wilson and 
Nicoll, 2001). Specifically, our group has found that pyramidal neurons (PNs) can express 
DSI, but not interneurons (INs), even though all subsets of neurons tested received 
cannabinoid-sensitive inhibitory inputs (Lemtiri-Chlieh and Levine, 2007).  
 
      DSI also exhibits laminar-specific expression pattern in the somatosensory cortex –
most layer 2/3 and a small population of layer 5a pyramidal neurons display eCB-
mediated DSI (Bodor et al., 2005). Further, our lab have reported that the eCBs have 
differential effects on excitation and inhibition across cortical layers. We have shown  that 
glutamatergic and GABAergic inputs to layer 5 PNs of mouse somatosensory cortex are 
differentially regulated following depolarization-induced endocannabinoid release, with 
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DSE much more prominent than DSI as a majority of inhibitory inputs were cannabinoid 
insensitive (Fortin and Levine, 2007; Lemtiri-Chlieh and Levine, 2007).  
 
      The attempts to identify the specific endogenous ligand involved have yielded 
contradicting results. Inhibition of MAGL extends DSI, thus 2-AG is considered as the 
eCB that mediates DSI (Hashimotodani et al., 2007c; Makara et al., 2005). In DAGLα 
mice, DSI and DSE are abolished suggesting the involvement of DGL. However, many 
other studies using various DAGL inhibitors have reported no inhibition of DSI/DSE (Min 
et al., 2010) indicating that 2-AG is not involved in the process. In light of negative results, 
we cannot exclude the role of 2-AG in modulating synaptic plasticity as there are other 
alternative pathways to synthesize 2-AG. 2-AG can be synthesized by hydrolysis of PI via 
phospholipase A1 (PLA 1) and lysophosphatidylinositol specific PLC (Tsutsumi et al., 
1994) or by conversion of 2-arachidonoyl lysophosphatidic acid (LPA) to 2-AG (Nakane 
et al., 2002) 
 
1.3.2 Endocannabinoid-mediated long-term plasticity 
     eCBs mediate several forms of long-term depression (LTD) at both excitatory (eCB-
LTD) and inhibitory synapses (eCB-iLTD). The first eCB-LTD at excitatory synapses was 
reported in dorsal striatum (Gerdeman et al., 2002) and nucleus accumbens (Robbe et 
al., 2002). At the same time, eCB-iLTD was observed in the amygdala (Marsicano et al., 
2002). Later LTD/iLTD was observed in sensory cortex (Bender et al., 2006; Crozier et 
al., 2007; Huang et al., 2008; Jiang et al., 2010; Lefort et al., 2013; Min and Nevian, 2012; 
Nevian and Sakmann, 2006; Sjostrom et al., 2003; Sjostrom et al., 2004), prefrontal 
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cortex (Chiu et al., 2010; Lafourcade, 2009), hippocampus (Chevaleyre and Castillo, 
2003; Chevaleyre and Castillo, 2004; Chevaleyre et al., 2007; Yasuda et al., 2008), 
cerebellum (Safo and Regehr, 2005) and basal lateral amygdala (Azad et al., 2004; 
Marsicano et al., 2002). Induction of eCB-LTD also requires an increase in intracellular 
Ca2+ and activation of CB1 receptors. However, CB1 receptor activation is not necessary 
for the maintenance phase of eCB-LTD (Chevaleyre and Castillo, 2003). Different 
signaling pathways mediate the long-lasting suppression of transmitter release compared 
to eCB-STD.  The cyclic AMP/protein kinase A (cAMP/PKA) pathway might be a pathway 
for the downstream signaling cascade mediating eCB-iLTD (Heifets and Castillo, 2009). 
Indeed, theta burst stimulation (TBS)-induced eCB-iLTD in hippocampus is prevented by 
blocking presynaptic cAMP/PKA signaling. Further, the active zone protein RIM1α, which 
can be phosphorylated by PKA, is required for eCB-iLTD, indicating that activation of 
CB1R may lead to regulation of the release machinery for GABA (Chevaleyre et al., 
2007).  
 
    eCB-mediated timing dependent plasticity (tLTD) has been reported at different 
excitatory synapses in the cortex and hippocampus.  For example, at layer 5 pyramidal 
neurons in visual cortex tLTD at excitatory synapses requires eCB release. The tLTD 
induction requires both CB1R and NMDA receptor activation (Sjostrom et al., 2003). A 
similar tLTD protocol has been reported at layer 4 to layer 2/3 excitatory synapses of the 
somatosensory cortex (Bender et al., 2006). In prefrontal cortex, 10 minutes of 10 Hz 
stimulation at layer 2/3 afferents has been reported to induce eCB-LTD in layer 5/6 
pyramidal neurons which requires activation of postsynaptic mGluR5 and PLC signaling.  
                                                                                         
13 
 
The authors also suggest that 2-AG is the specific ligand involved in this form of LTD 
(Lafourcade, 2009). In layer 5 of prefrontal cortex, coactivation of CB1R and dopamine 
type 2 receptors triggers eCB-iLTD. This iLTD also requires activation of mGluR1 for 
induction (Chiu et al., 2010). eCB-iLTD can be induced by a combination of electrical and 
chemical stimulation. For instance, pairing subthreshold stimulation with a low dose of 
DHPG induced iLTD comparable to strong TBS alone in hippocampal CA1 neurons 
(Younts et al., 2013). Yet another study in hippocampus indicates that high frequency 
stimulation (HFS, 100Hz/1s, 2 trains with 20s inter-train interval) can elicit mGluR 
dependent eCB-iLTD (Chevaleyre and Castillo, 2003).  The LTD can be developmentally 
regulated, suggesting a role in shaping cortical circuits during postnatal development.  In 
layer 2/3 pyramidal neurons of visual cortex, TBS of layer 4 axons induces eCB-LTD in 
mGluR 5 dependent, but NMDA receptor independent. However, no LTD is observed in 
these animals past their critical period (Huang et al., 2008).   
 
     It has been hypothesized that eCBs may modulate LTP of glutamatergic transmission 
via disinhibition of postsynaptic neurons through the suppression of GABA release. This 
form of LTP was first observed in the hippocampus. Carlson and others recorded whole 
cell EPSCs and field EPSPs simultaneously in the CA1 region of hippocampus. A 
combination of postsynaptic depolarization and weak presynaptic stimulation together 
induced LTP of EPSCs but not fEPSPs. EPSC-LTP was completely abolished in the 
presence of CB1 receptor antagonists, indicating that eCB-STD at inhibitory synapses 
could facilitate LTP induction at glutamatergic synapses (Carlson et al., 2002). 
Conversely, eCB-LTD at inhibitory synapses can also facilitate LTP induction at nearby 
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glutamatergic synapses in hippocampal slices. This form of LTP requires both GABAergic 
synaptic function and eCBs (Chevaleyre and Castillo, 2004). However, further studies are 
needed to understand the mechanisms underlying eCB-mediated LTP of excitatory 
synaptic transmission.  
 
     Two recent studies reported a novel form of LTP mediated by endocannabinoids. In 
rat hippocampal slices, LTP was induced in the lateral perforant path (LPP) pathway by 
high frequency stimulation. This induction protocol activates NMDA and mGluR5 type 
glutamate receptors and increases postsynaptic calcium content and engages in 
production of 2-AG. 2-AG acts on presynaptic CB1 receptors thereby initiating signaling 
via small GTPases. This leads to the assembly and reorganization of latrunculin-sensitive 
actin filaments causing an enhancement of evoked transmitter release (Wang et al., 
2016). Further, the authors show that the CB1Rs activate two signaling cascades – 
pregnenolone sensitive and pregnenolone insensitive. The pregnenolone-insensitive 
cascade stimulates integrin-associated focal adhesion kinases (FAK), which targets small 
GTPases. Integrin, CB1R and activation of small GTPases act together to aid in 
reorganization of actin filaments resulting in enhanced glutamate release probability by 
increased vesicle docking.  The involvement of FAK in synaptic plasticity indicates that 
these kinases can modulate changes in gene expression and support the neural changes 
along with eCBs in LTP (Wang et al., 2018). A more recent study in 2018, in acute 
hippocampal slices, has shown that low frequency stimulation coupled with action 
potential and slow depolarization induces eCB-LTP at these synapses. The authors 
confirm that eCB-mediated DSI during stimulation facilitates LTP at these synapses. In 
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addition, the stimulation causes release of endogenous BDNF which facilitates LTP at 
these synapses (Maglio et al., 2018). This is a novel form of LTP where eCBs facilitate 
LTP via interaction with BDNF signaling. In the next section, we will discuss BDNF and 
its role in synaptic plasticity. 
 
To summarize this section,  
(i) eCBs are retrograde messengers that act on presynaptic CB1 receptors to 
suppress neurotransmitter release (including GABA and glutamate).  
(ii) eCBs can be released via calcium induced release, receptor driven release or 
calcium assisted receptor driven release (as explained in section 1.2.3).  
(iii) The best characterized ligands are 2-AG and AEA – however, most studies 
have identified 2-AG as the endogenous ligand mediating short-term and long-
term synaptic plasticity.   
(iv) eCBs can modulate LTP of glutamatergic transmission via disinhibition of 
postsynaptic neurons through the suppression of GABA release  
 
     eCB-LTD is well established at both excitatory and inhibitory synapses, yet it is unclear 
how long is the maintenance phase of LTD? What are the accompanied changes due to 
long lasting depression – is there a structural change of the synapses, dendritic spines 
and how it does relate to synaptic function of the synapses?  Can these associated 
changes in synapses be reversed in the maintenance phase? Instead of using existing 
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stimulation protocols to elucidate LTD, can we use DSI stimulation paradigms repeatedly 
to induce LTD?  
 
     To further add to the complexity of the eCBs is its interaction with other 
neuromodulatory systems (explained in detail in section 1.6). How do these interactions 
occur? What are the associated changes at synaptic and functional levels? What are the 
mechanisms and signaling pathways that aid in these interactions? These questions 
needs to be addressed in the future.  These interactions might represent a novel class of 
eCB-mediated plasticity, for instance, CB1Rs may stimulate the release of a key factor or 
activate a signaling pathway that helps in inducing synaptic plasticity at these synapses 
as discussed in these (Maglio et al., 2018; Wang et al., 2018; Wang et al., 2016) studies.  
 
1.4 Brain-derived neurotrophic factor (BDNF) 
1.4.1 BDNF, TrkB receptors 
      Brain derived neurotrophic factor (BDNF) belongs to the neurotrophin gene family and 
promotes neuronal development and differentiation. It is also a potent modulator and/or 
mediator of synaptic plasticity. Acutely, BDNF enhances glutamatergic transmission and 
suppresses GABAergic transmission via both pre- and postsynaptic mechanisms. BDNF 
can be released in an activity-dependent manner and has been found to be essential for 
long-term potentiation and some forms of long-term depression (Gottmann et al., 2009).  
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      BDNF produces its effects through different classes of receptors: the high affinity full 
length tropomyosin receptor kinase B (TrkB, Kd ~ 10-11M) that mediates most of BDNF 
signaling including its role in synaptic plasticity; the truncated form of TrkB (TrkB-T1) which 
lacks protein tyrosine kinase activity, and the lower affinity, pan-neurotrophin receptor, 
p75NTR (Berg et al., 1991; Kaplan et al., 1991; Rodriguez-Tebar and Barde, 1988).  TrkB-
T1 is widely distributed in the brain and its level of expression increases with age (Fryer 
et al., 1996; Ohira et al., 1999). It has been implicated as a dominant negative inhibitor of 
full length TrkB function, however, the underlying signaling pathways are largely unknown 
(Eide et al., 1996; Saarelainen et al., 2000).  On the other hand, p75NTR primarily acts 
in opposition to BDNF/TrkB effects, for example, its activation promotes apoptosis 
(Barrett, 2000; Bunone et al., 1997; Majdan et al., 1997) and inhibits neurite outgrowth 
(Kohn et al., 1999; Walsh et al., 1999; Yamashita et al., 1999).  
 
      The high affinity TrkB receptor is a single transmembrane domain receptor tyrosine 
kinase. Upon binding, TrkB receptors dimerize and phosphorylate tyrosine residues which 
enhances catalytic activity of the kinase. Sometimes, TrkB receptors can 
autophosphorylate to activate downstream signaling pathways. Upon BDNF binding and 
receptor activation, three downstream signaling pathways are activated via tyrosine 
phosphorylation: phospholipase CƔ pathway (PLCƔ), Ras/mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinases (PI3K)/Akt pathways. Activation of the 
PI3K/Akt and MAPK pathways are critical for neuronal survival and differentiation. 
However, MAPK pathways are also involved in certain forms of chemically-induced LTP 
that requires endogenous BDNF/TrkB signaling.  Activation of PLCƔ leads to cleavage of 
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phosphatidylinositol 4,5-bisphosphate (PIP2) into second messengers inositol 
triphosphate (IP3) and diacylglycerol (DAG). IP3 induces Ca2+ release from calcium stores 
upon binding to its receptor and thus increases intracellular calcium concentration. DAG 
is involved in several intracellular signaling pathways, one of which is stimulation of 
protein kinase C, which is required for neurite outgrowth. DAG also serves as a precursor 
to the endocannabinoid 2-arachidonoylglycerol via DAG lipase. Both these pathways 
have been found to be involved in modulating the effect of BDNF on inhibitory synaptic 
transmission (Henneberger et al., 2002; Jovanovic et al., 2004). 
 
1.4.2 Distribution of BDNF and TrkB receptors 
     TrkB mRNA and protein are widely distributed across the brain, with highest densities 
in the neocortex, hippocampus, amygdala, striatum, cerebellum and dorsal root ganglia 
(Ernfors et al., 1990; Gorba and Wahle, 1999; Hofer et al., 1990).  The mRNA levels reach 
their peak at birth and remain stable throughout adulthood in most regions of rat forebrain 
(Fryer et al., 1996), while TrkB protein reaches peak density as well as stable layer 
distribution around postnatal day 10, with highest density in neocortical layers 2/3 and 5 
(Cabelli et al., 1996). At the synaptic level, TrkB is expressed in both postsynaptic 
dendrites and presynaptic terminals in the hippocampus and cortex (Aoki et al., 2000; 
Drake et al., 1999).  Immunoreactive TrkB receptors are expressed at both glutamatergic 
and GABAergic synapses (Drake et al., 1999). The TrkB presence in both pre- and 
postsynaptic components suggests that BDNF can modulate synaptic plasticity at both 
locations.   
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      BDNF mRNA is widely distributed throughout the brain including cerebral cortex 
(Hofer et al., 1990), hippocampal formation, thalamus, hypothalamus, amygdala, 
olfactory lobes and spinal cord (Ernfors et al., 1990; Hofer et al., 1990; Phillips et al., 
1990; Wetmore et al., 1990). BDNF protein is widely distributed in cerebral cortex, 
hippocampus, amygdala and thalamus (Conner et al., 1997; Wetmore et al., 1991). In 
rodents BDNF mRNA and protein levels peak shortly after birth and remain stable 
(Friedman et al., 1991; Maisonpierre et al., 1990; Patz and Wahle, 2006). BDNF can be 
found both in neurons and glia and can be released from both neurons and glia in 
response to activity (Conner et al., 1997; Wetmore et al., 1990; Wu et al., 2004).  At the 
subcellular level, BDNF mRNA is distributed in somatic structures and in dendritic 
compartments but absent in axons (An et al., 2008; Capsoni et al., 1999). At the 
subcellular level, BDNF protein is observed in axons within the superior colliculus, 
amygdala, dentate gyrus granule cells and CA3 pyramidal cells. BDNF protein is also 
found in the postsynaptic density and dendritic shafts of cerebral cortical pyramidal 
neurons. Further, ultramicroscopic studies have identified BDNF in endoplasmic 
reticulum and in vesicles at extrasynaptic, presynaptic, and postsynaptic sites indicating 
that the BDNF can be released synaptically as well as extrasynaptically (reviewed in 
(Edelmann et al., 2014)).   
 
1.4.3 Release of endogenous BDNF 
       After transport of BDNF-containing vesicles into axons and dendrites, BDNF is 
secreted constitutively and in an activity-dependent manner in response to electrical 
activity. BDNF release can be triggered by (i) calcium influx through ionotropic glutamate 
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receptors or voltage gated channels (VGCCs) (Hartmann et al., 2001); (ii) activation of 
Group I mGluR receptors, which subsequently triggers IP3-mediated Ca2+ release from 
intracellular stores (Canossa et al., 2001). BDNF can be released from both pre- and 
postsynaptic sites.  The most common stimulation protocols, high frequency stimulation 
or theta burst stimulation (TBS), can induce BDNF release in hippocampal or cortical 
neurons (Dean et al., 2012). In addition, depolarization of hippocampal neurons, rhythmic 
neuronal discharges and spontaneous electrical network activity can induce BDNF 
release ((Matsuda et al., 2009) also reviewed in (Edelmann et al., 2014)). For instance, 
Aicardi and colleagues have shown that BDNF can be released with low frequency 
stimulation in cortical slices.  BDNF release is also regulated by intravesicular pH (Aicardi 
et al., 2004).  
 
     Besides the distribution of receptors, induction and release of BDNF, yet another factor 
that needs to be addressed is the time window for BDNF function – since BDNF can act 
instructively and permissively at synapses. For instance, using specific antibodies to 
BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5), Chen and colleagues have 
identified that BDNF but not NT-3 or NT-4/5 impairs LTP induced by TBS. However, they 
show that LTP is impaired only when BDNF is blocked before and/or during TBS 
stimulation but not after stimulation, suggesting the release of BDNF occurred in a specific 
time period (Chen et al., 1999). In contrast, Kossel and colleagues show that blocking 
BDNF shortly after LTP induction is sufficient to impair LTP indicating that the released 
BDNF acts in an instructive capacity to maintain LTP (Kossel et al., 2001). Taken 
together, these studies suggest that the induction paradigms, release sites of BDNF and 
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time window of BDNF presence have an impact on the effect of BDNF on synaptic 
transmission.  
 
1.5 Functional role of BDNF in synaptic plasticity 
       It has been widely established that BDNF is an important modulator of synaptic 
plasticity. However, very little is known about the release and time of action of BDNF 
when synaptic plasticity is induced in a given paradigm. The most pressing open ended 
questions in the field about BDNF are: (i) Does BDNF act as a modulator or mediator of 
synaptic plasticity. (ii) Is BDNF secreted from presynaptic, postsynaptic, and/or glial sites 
to induce the synaptic changes? What are the relevant patterns of activity that trigger 
BDNF release? (iii) What factors decide whether a BDNF dependent synaptic change is 
mediated by pre- or post-synaptic alterations?  The below section will attempt to answer 
some of these questions and enhance our knowledge of the role of BDNF in synaptic 
plasticity.  
 
1.5.1 Acute effect of BDNF on synaptic transmission 
     Acute application of BDNF modulates synaptic transmission at both excitatory and 
inhibitory synapses in cerebral cortex and hippocampus. For instance, BDNF enhances 
glutamate transmission in hippocampal and cortical cultures (Lessmann and Heumann, 
1998; Levine et al., 1995; Li et al., 1998) in hippocampal acute slices (Madara and Levine, 
2008) and in layer 2/3, 5 (Madara and Levine, 2008) of cortical slices from rodents. These 
results match up with anatomical locations in which TrkB receptors are expressed.  
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      BDNF enhances excitatory synaptic transmission both presynaptically via 
enhancement of glutamate release as well as postsynaptically via NMDA receptor 
enhancement. Specifically, BDNF rapidly enhances action-potential independent current 
or miniature excitatory postsynaptic current (mEPSC) decay time and frequency 
suggesting BDNF has both presynaptic and postsynaptic mechanisms in the same 
preparation (Madara and Levine, 2008). By selectively blocking postsynaptic TrkB 
receptors by intracellular application of trk inhibitor inhibits the mEPSC decay time but not 
the mEPSC frequency. The presynaptic effect is mediated by presynaptic TrkB and 
NMDA receptors as blocking with the receptor antagonist inhibited the effect (Madara and 
Levine, 2008).  
 
     However, BDNF does not affect evoked glutamate release in response to single spikes 
in hippocampus (Frerking et al., 1998) or in layer 5 somatosensory cortex (Madara and 
Levine, 2008). This suggests that the effects of BDNF on evoked release may depend on 
specific action-potential activity patterns. It is also important to note that the spontaneous 
and evoked glutamate release may utilize different vesicle pools that are regulated 
differently. The visualization of glutamate release events at individual synapses shows 
that there is a preference for evoked versus spontaneous glutamate transmission that is 
determined by release machinery at active zones (reviewed in (Andreae and Burrone, 
2018; Atasoy et al., 2008; Crawford and Kavalali, 2015; Kaeser and Regehr, 2014; Walter 
et al., 2014)). For instance, Melom and colleagues have reported that spontaneous 
release occurs from all active zones but suggest that some zones are incapable of 
supporting evoked release and hence remain as spontaneous synapses, early in 
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development. However, as synapses mature, additional regulatory proteins are acquired 
that allow for better control of synaptic release and thus enable evoked release rather 
than spontaneous release (Melom et al., 2013). Spontaneous release at glutamatergic 
synapses has been associated with formation of dendritic spines, synaptic stabilization 
and long-term forms of synaptic plasticity (reviewed in (Andreae and Burrone, 2018; 
Melom et al., 2013; Peled et al., 2014; Walter et al., 2014)). For instance, application of 
BDNF on layer 4 visual cortex increases the growth of basal and apical dendritic arbors. 
The authors show that BDNF-induced growth is completely abolished in the presence of 
glutamate receptor antagonists in the basal dendrites, suggesting that spontaneous 
glutamate release is needed for this BDNF-induced growth of dendritic arbors (McAllister 
et al., 1996).  In hippocampus, disruption of spontaneous glutamate release for several 
hours leads to homeostatic regulation of inhibitory synapses through a mechanism that 
relies on activation of postsynaptic metabotropic glutamate and cannabinoid receptors 
and release of endocannabinoids (Zhang et al., 2009b). During the developmental period 
where neurotransmitter release is exclusively spontaneous, blocking NMDA receptors 
with an antagonist causes a reduction in dendritic arbor complexity while blocking NMDA 
at later stages did not have any effect. This study suggests that the glutamate might act 
as a growth-promoting cue. In cultured hippocampal cells, spontaneous glutamate 
release activates NMDA receptors to suppress local protein synthesis in dendrites (Sutton 
et al., 2006; Sutton et al., 2004). The majority of the published work has focused on 
investigating the role of spontaneous glutamate release. The mechanisms by which 
spontaneous GABA release occurs is relatively unknown compared to glutamate release.   
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     While most studies show that the acute application of BDNF suppresses GABAergic 
transmission, the mechanisms by which BDNF modulates inhibitory neurotransmission 
are unclear. In CA1 region of hippocampus, BDNF application causes a reduction in the 
amplitude of evoked inhibitory postsynaptic currents. Also, BDNF causes a reduction in 
the paired-pulse ratio and decreases in the coefficient of variation suggesting a 
presynaptic site of action (Frerking et al., 1998). In rat hippocampal cultures, BDNF 
causes a rapid reduction in postsynaptic GABA receptor number that is responsible for a 
decrease in mIPSC amplitude (Brunig et al., 2001). A study by Mizoguchi et al., 2006 
suggests that the effect of BDNF on GABA release is dependent on age. BDNF 
suppresses mIPSC frequency and amplitude in hippocampal preparations of age P14 
and P21 rats but not in P7 rats (Mizoguchi et al., 2006).  A decrease in mIPSC frequency, 
mIPSC amplitude and decrease in release probability is observed in visual cortex of 
BDNF knockout mice suggesting that the BDNF impairment is presynaptic (Abidin et al., 
2008; Abidin et al., 2006). In cerebellar granule cells, BDNF decreases both the amplitude 
and frequency of spontaneous and miniature postsynaptic currents suggesting both pre- 
and postsynaptic effects (Cheng and Yeh, 2003). This effect of BDNF is blocked by 
inclusion of TrkB antagonist to the postsynaptic cell in cerebellar granule cells (Cheng 
and Yeh, 2003).  
 
     Other studies have reported acute postsynaptic effects of BDNF triggered by TrkB 
activation in hypothalamus (Hewitt and Bains, 2006), cerebellum (Brunig et al., 2001), 
cultured neurons from hippocampus (Cheng and Yeh, 2003; Jovanovic et al., 2004), 
mouse superior colliculus (Henneberger et al., 2005), visual cortex (Mizoguchi et al., 
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2003), rat substantia gelatinosa (Lu et al., 2012) and rat supraoptic nucleus (Ohbuchi et 
al., 2009).   
 
    Collectively, these diverse effects explain the varied findings regarding BDNF on 
synaptic transmission as the effects of BDNF depend on several factors including age, 
area of interest, developmental stage of brain, and cell type. Further, these early studies 
did not account for the role of retrograde messengers in their preparations. For instance, 
at inhibitory synapses of somatosensory cortex, BDNF causes reduction in the amplitude 
of spontaneous inhibitory activity via postsynaptic TrkB receptors and the expression is 
presynaptic. We have shown that the eCBs are the retrograde messengers that mediate 
the effect of BDNF in this brain region (Lemtiri-Chlieh and Levine, 2010). Similarly, we 
have also shown that BDNF triggers the release of eCBs at layer 5 excitatory synapses 
of somatosensory cortex (Yeh et al., 2017).  Taken together, these results suggest BDNF 
utilizes several mechanisms to modulate inhibitory neurotransmission resulting in 
different outcomes, which adds to the complexity of understanding the effect of BDNF on 
synaptic transmission across different brain regions.  
 
1.5.2 BDNF and long-term synaptic plasticity  
       Along with its acute effects on synaptic transmission, endogenously-released BDNF 
plays an important role in several forms of activity-dependent plasticity, including long- 
term potentiation (LTP). The endogenous role of BDNF/TrkB signaling is well established 
in CA1, CA3 of hippocampus and cerebral cortex. The released BDNF can modulate 
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synaptic efficacy either by changes in presynaptic transmitter release or by postsynaptic 
transmitter sensitivity (Itami et al., 2003; Levine et al., 1995) to induce a long lasting 
potentiation. The role of endogenous BDNF was reported first in heterozygous BDNF 
knockout mice, in which LTP was dramatically reduced at Schaffer collateral-CA1 
synapses (Korte et al., 1995). Similar results have been reported in animals that lack TrkB 
receptors in CA1 (Xu et al., 2000) or forebrain (Minichiello et al., 1999). In the knockout, 
LTP can be rescued by exogenous application of BDNF for several hours (Patterson et 
al., 1996) or by re-expression of BDNF through viral-mediated gene transfer (Korte et al., 
1996). Several other studies have indicated a role for endogenous BDNF in hippocampus, 
cortex, amgydala and ventral tegmental area.  Application of a TrkB receptor antagonist 
or the BDNF scavenger TrkB-IgG fusion protein prevented LTP in hippocampus and 
cortical slices (Akaneya et al., 1997; Chen et al., 1999; Kang et al., 1997). The 
requirement for BDNF in plasticity is experience-dependent. In hippocampal slices, it has 
been shown that the high frequency stimulation-induced LTP does not require BDNF 
signaling while endogenous BDNF is required for mild stimulation. Similarly, some forms 
of LTD require BDNF while short term depression or DSI does not require BDNF (Aarse 
et al., 2016). 
 
      The role of BDNF in LTP is highly diverse depending on the type of preparation and 
stimulation protocol. For example, LTP induced by tetanic stimulation in the hippocampus 
is prevented by global knockout of TrkB receptors, but is not impaired by selective 
knockout of postsynaptic TrkB, suggesting that presynaptic BDNF/TrkB signaling 
mediates this effect (Xu et al., 2000). Similarly, in layer 5 of the visual cortex, BDNF is 
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secreted from postsynaptic sites and acts on presynaptic TrkB receptors to induce LTP 
(Inagaki et al., 2008). In cocaine-withdrawn animals, BDNF facilitates LTP induction at 
layer 2/3 to layer 5 synapses in medial prefrontal cortex by suppressing GABAergic 
inhibition, thereby enhancing pyramidal neuron excitability (Lu et al., 2010). This effect of 
BDNF was mediated by postsynaptic TrkB receptors as downregulation of postsynaptic 
TrkB receptors with a specific siRNA blocked LTP expression (Lu et al., 2010). In 
transgenic TrkBF616A mice (in these mice, TrkB can be rapidly and reversibly inhibited 
using nanomolar concentrations of 1NMPP1, a derivative of the kinase inhibitor PP1) , 
the authors found that postsynaptic BDNF/TrkB signaling was not required for pairing-
induced LTP, but it was critical for presynaptic facilitation of immature CA3-CA1 
synapses. This study indicates that BDNF binds to presynaptic TrkB receptors, initiating 
signaling cascades resulting in an increase in transmitter release at these synapses 
(Sallert et al., 2009). In addition, the F616A mutation in TrkB receptor has little or no effect 
on BDNF-mediated TrkB signaling under basal conditions, i.e. in the absence of 1NMPP1 
(Chen et al., 2005). Similar to acute slices, LTP observed in hippocampal cultures also 
shows mixed pre- and postsynaptic roles (reviewed in (Edelmann et al., 2014)).  
 
     Spike timing-dependent plasticity (STDP) is considered a more physiological form of 
plasticity compared to high frequency stimulation-induced plasticity. STDP has been 
observed in different brain regions including visual cortex (Seol et al., 2007), amgydala 
(Jung et al., 2010), hippocampus (Buchanan and Mellor, 2010; Edelmann et al., 2015; 
Edelmann and Lessmann, 2013; Zhang et al., 2009a) and striatum (Pawlak and Kerr, 
2008). A few studies have indicated a role of endogenous BDNF in this form of STDP. 
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For immature hippocampal mossy fiber (MF) synapses at early postnatal stages, a BDNF 
and cAMP/PKA dependent STDP was demonstrated (1:1 pairing 10x at 0.1 Hz) 
(Sivakumaran et al., 2009). BDNF was assumed to be released postsynaptically under 
these conditions, acting retrogradely and inducing presynaptic expression of STDP 
(Sivakumaran et al., 2009).  It has also been shown that the STDP is impaired in 
pyramidal neurons in the infralimbic medial prefrontal cortex from BDNFmet/met mice. 
(Pattwell et al., 2012). These mice recapitulate the specific phenotypic properties of the 
human BDNF Val66Met polymorphism, impairing regulated release of BDNF, but not 
constitutive release of BDNF (Chen et al., 2006). TrkB-IgG are scavengers of extracellular 
BDNF, consisting the BDNF binding region of BDNF specific TrkB receptor fused to the 
human Fc region. Upon application, TrkB-IgG binds and inactivates the released BDNF. 
In acute hippocampal slices, using TrkB-IgG to block BDNF signaling, Lu and colleagues 
found that BDNF is required for STDP as blocking BDNF disrupted the STDP.  The 
authors found that the effects of BDNF application can be mimicked by the low frequency 
pairing of glutamate release and postsynaptic spiking as this protocol is sufficient to 
trigger the release of BDNF in a timing-dependent manner (Lu et al., 2014).  In acute 
hippocampal slices, three different pairing protocols were used to induce STDP. 
Interestingly, the expression mechanism (pre versus post) and the dependency of BDNF 
was strikingly different between the protocols. The pairing protocol is pre-post pairings 
with either a 1EPSP/1 AP (70-100 repeats at 0.5Hz; 1:1) or 1EPSP/4AP (20-35 repeats 
at 0.5Hz; 1:4). The authors found that 1:4 protocol is postsynaptic and requires BDNF for 
the induction and maintenance of STDP while the 1:1 protocol is presynaptic and is 
independent of BDNF/TrkB signaling (Edelmann et al., 2015). Taken together, these 
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studies show both pre- and/or postsynaptic BDNF effects in LTP indicating that BDNF 
can be released both pre- and postsynaptically and can alter pre- and postsynaptic 
functions at a given synapse. 
 
      BDNF can also contribute to LTD by interacting with endocannabinoids. At layer 2/3 
inhibitory synapses of somatosensory cortex, theta burst stimulation (TBS) induces an 
eCB-mediated iLTD that is independent of mGluR signaling. This form of iLTD requires 
endogenous BDNF signaling and PLC Ɣ signaling to trigger the release of eCBs (Zhao et 
al., 2015). Similar to the study described above, weaker stimuli did not cause LTD, 
however, in combination with exogenous BDNF, weaker stimuli yielded a long-lasting LTD 
(Zhao et al., 2015).  In another study, BDNF has been shown to induce two different forms 
of depression – short term depression and long-term depression in ventral tegmental area 
dopamine neurons.  Both forms of plasticity require eCB signaling as blocking CB1 
receptors blocked the depression at these synapses (Zhong et al., 2015). These studies 
helped in understanding of synaptic plasticity to highlight the interactions between BDNF 
and other neuromodulatory systems.  
 
     Several lines of evidence described in this section suggest that BDNF regulates short- 
and long-term synaptic plasticity. To summarize these studies, 
(i)  BDNF can be secreted from axons, dendrites and astrocytes.  
(ii) BDNF can affect synaptic transmission at both inhibitory and excitatory 
synapses in different brain regions.  
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(iii) The effect of BDNF on synaptic transmission is also dependent on age, sex, 
developmental stage, and cell type.  
Depending on the context – BDNF 
(i) can be both, a mediator (that is critical for triggering a set of events in synaptic 
plasticity) or modulator (favoring either induction or maintenance of synaptic 
plasticity) of synaptic plasticity,  
(ii) can be released either pre- or postsynaptically in neurons, and  
(iii) can alter pre- and postsynaptic functions at the same synapse. Whether BDNF 
has a permissive or instructive function in a given LTP paradigm is relatively 
unexplored.  
 
    Future research in the field should be focused on (i) investigation of BDNF release sites 
and mode of release (constitutive vs regulated). (ii) Investigation of role of BDNF in 
response to different patterns of electrical stimulation. (iii) Investigation of BDNF and TrkB 
signaling at GABAergic and/or glutamatergic synapses in astrocytes and microglia. (iv) 
Investigation of role of BDNF as permissive (facilitating the synaptic responses that favor 
the induction phase of LTP) or instructive (BDNF signaling is required only for expression 
of LTP) in a given plasticity paradigm and (iv) investigation of BDNF/TrkB system 
interactions with other neuromodulatory systems. BDNF interactions with eCBs are 
described in detail in the following section. 
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1.6 Crosstalk between BDNF and endocannabinoid signaling 
     Traditionally, BDNF is known for its trophic role in neurodevelopment, such as 
neuronal migration, neuronal survival and neurogenesis and neuronal maturation (Barde, 
1994; Lykissas et al., 2007; Newton and Duman, 2004). Over the past two decades, 
BDNF signaling has been highlighted as an important modulator of synaptic transmission 
and synaptic plasticity (Edelmann et al., 2014; Gottmann et al., 2009).  On the other hand, 
endocannabinoid signaling was discovered and initially studied in the context of synaptic 
plasticity (reviewed in (Castillo et al., 2012)) and recently has also been shown to be 
involved in embryonic neuronal development, axonal navigation, neural progenitor 
proliferation and pyramidal specification in developing brain ((Oudin et al., 2011), 
reviewed in detail (Diaz-Alonso et al., 2012; Galve-Roperh et al., 2013)). Further, the 
expression profile of TrkB receptors and CB1 receptors have an overlapping pattern – 
high expression of both receptors are present in cerebral cortex, hippocampus, amygdala, 
striatum and cerebellum of brain regions (Egertova et al., 2003; Fryer et al., 1996; Gomes 
et al., 2006; Hofer et al., 1990; Masana et al., 1993; Matsuda et al., 1993; Moldrich and 
Wenger, 2000; Tsou et al., 1998). Within the neocortex, TrkB is highly localized to layers 
2/3 and 5 of cortex (Cabelli et al., 1996; Fryer et al., 1996; Miller and Pitts, 2000) and CA1 
of hippocampus and CB1 receptors are highly expressed in the same regions (Egertova 
et al., 2003; Marsicano and Lutz, 1999; Matsuda et al., 1993; Tsou et al., 1998). These 
anatomical studies corroborate the possibility of functional interactions between BDNF 
and eCB signaling in the neocortex and hippocampus. 
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     During development, eCBs provide a mechanism for the molecular control of 
interneuron migration and differentiation by regulating BDNF actions. During cortical 
interneuron development, AEA acts as a chemo-attractant and regulates migration of 
CCK-expressing interneurons by TrkB receptor transactivation. It also blocks BDNF-
induced neural differentiation of cortical interneurons which suggests that eCBs govern 
interneuron placement, migration and specification during corticogenesis (Berghuis et al., 
2005). Relevant studies about BDNF-eCB interactions came from animal models of 
depression, in which activation of one system affects the other system. For instance, 
BDNF and eCBs are both well known for their neuroprotective effects against depression, 
disruption of either of the signaling pathways has been found to be related to depression. 
It has been suggested that the anti-depressant effects of eCBs are mediated by BDNF. 
CB1R activation leads to the increased expression of BDNF (Aso et al., 2008; Vinod et 
al., 2012). Chronic exposure to THC, the psychoactive component of marijuana, causes 
an upregulation of BDNF in vivo in areas implicated in reward processes (Butovsky et al., 
2005). Further, BDNF administration to hippocampus reversed the enhanced stress 
response in CB1R knockouts (Aso et al., 2008) while BDNF levels are decreased in 
CB1R-null mice (Aso et al., 2008). Also, eCBs modulate the level of BDNF released by 
activating the downstream signaling pathways of BDNF in regulating the fear extinction 
model in mice (Bennett et al., 2017). In another study of primary cerebellar neurons, 
corticotrophin releasing hormone (CRH) increases the expression of BDNF while the 
effect is blocked by inhibiting the eCB system.  Similarly, depolarization-induced BDNF 
synthesis is blocked by the prolonged application of a CB1 agonist (Bayatti et al., 2005). 
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    BDNF also regulates endocannabinoid signaling (Luongo et al., 2014). For instance, in 
cultured cerebellar granule neuronal cultures, BDNF enhances neuronal sensitivity to 
eCBs by increasing the expression of CB1Rs and decreasing MAGL expression (Maison 
et al., 2009). These interactions between BDNF and endocannabinoids are also observed 
at synaptic level. Theta burst stimulation (TBS)-induced LTP and LTD simultaneously at 
layer 4 to layer 2/3 excitatory synapses in visual cortex, however, the net effect was a 
potentiation of synaptic transmission. The LTP is mediated by the endogenous release of 
BDNF by the TBS paradigm while the LTD is mediated by TBS-induced eCBs as the 
effect is blocked by TrkB receptor and CB1 receptor antagonists respectively. Thus, the 
net effect observed is due to competing components of BDNF-mediated LTP against 
eCB-mediated LTD (Huang et al., 2008). Our lab has shown that at layer 2/3 inhibitory 
synapses of somatosensory cortex, BDNF triggers the release of endogenous 
cannabinoids via phospholipase C Ɣ (PLC Ɣ) signaling pathway that act retrogradely on 
presynaptic CB1 terminals to suppress GABA release (Lemtiri-Chlieh and Levine, 2010; 
Zhao and Levine, 2014). We also found that TBS induces a form of endocannabinoid-
mediated LTD that requires endogenous BDNF and PLC Ɣ signaling (Zhao et al., 2015). 
Similar to the visual cortex study described above, at layer 5 excitatory synapses of 
somatosensory cortex, we have shown that BDNF induces the release of endogenous 
cannabinoids and this effect opposes the direct presynaptic effects of BDNF (Yeh et al., 
2017).   
      
     In the striatum, BDNF inhibits CB1 receptor function selectively at inhibitory synapses 
by altering cholesterol metabolism and membrane lipid raft function (De Chiara et al., 
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2010; De Chiara et al., 2013). Yet another study in striatum shows that the CB1 receptor 
protects striatal cells from excitotoxicity via phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin complex 1 pathway. This pathway triggers the production of BDNF 
via activation of BDNF gene promoter IV (Blazquez et al., 2015).  These studies in 
striatum indicate different mechanisms by which BDNF and eCBs interact.  
      
     In hippocampus, prolonged BDNF treatment in vitro suppresses mGluR-induced eCB 
signaling while enhancing depolarization-induced eCB signaling at excitatory synapses, 
suggesting that BDNF employs different mechanisms to regulate eCB-mediated effects 
(Roloff et al., 2010). In dopamine neurons of ventral tegmental area of midbrain, BDNF 
facilitates two forms of eCB-mediated plasticity – DSI and LTD at inhibitory synapses. 
BDNF is also required for cocaine-induced reduction of GABAergic inhibition. However, 
in BDNF knockout mice, there is an impairment of cocaine-induced reduction of 
GABAergic inhibition, eCB-mediated iLTD at inhibitory synapses and potentiation of 
glutamatergic excitation indicating that BDNF interacts with eCBs for cocaine-induced 
synaptic plasticity (Zhong et al., 2015).  In rat barrel cortex, at layer 5 distal basal 
excitatory synapses, action potential barrages facilitate the release of eCBs. The released 
eCBs suppress inhibitory transmission but facilitate Ca2+ spike facilitation and BDNF 
dependent LTP of excitatory synaptic transmission. In addition, both BDNF and eCBs are 
endogenously released and facilitate this novel form of LTP indicating another mode of 
interaction between the neuromodulators (Maglio et al., 2018).  
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     Collectively, these studies suggest that the physiological and functional relevance of 
BDNF-eCB interactions might have a diverse impact on synaptic plasticity at both 
excitatory and inhibitory synapses in different brain regions, although much is still 
unexplored at this stage.  Understanding these interactions will help us in elucidating the 
differences between normal and diseased state of brain on synaptic transmission in 
different brain regions. 
 
      In this section, I have discussed interactions between BDNF and eCBs in different 
brain regions during neuronal development and in relation to synaptic plasticity. The set 
of studies in this thesis contributes further to our understanding of BDNF and its role in 
synaptic transmission and plasticity. BDNF has diverse effects depending on the 
particular context – excitatory vs inhibitory synapses, pre- versus postsynaptic receptor 
expression, and site of release. In addition, BDNF interacts with other neuromodulators 
and activates signaling pathways that can alter transcription factors and protein synthesis. 
Developing new approaches and tools to interfere with the expression and secretion of 
endogenous BDNF will be crucial to further advance our understanding of BDNF 
regulation of synaptic function.  
 
1.7 Rationale and hypothesis 
     The studies carried out in this dissertation examine the physiological interactions of 
BDNF and eCBs at hippocampal inhibitory synapses and cortical excitatory synapses. 
Our lab has previously shown that, in layer 2/3 of somatosensory cortex, the effect of 
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BDNF on inhibitory postsynaptic currents (IPSCs) is mediated by a retrograde effect on 
presynaptic terminals. We found that BDNF caused a suppression of IPSCs, which is 
blocked by the trk inhibitor K252a or the calcium chelator BAPTA applied to the 
postsynaptic cell, indicating the involvement of postsynaptic TrkB receptor activation and 
subsequent increase in intracellular calcium. Unexpectedly, the suppression of IPSCs 
was due to a decrease in presynaptic GABA release and not due to altered postsynaptic 
GABA receptor responsiveness.  BDNF causes an increase in the paired pulse ratio, 
increase in the coefficient of variation of evoked responses and a decrease in the 
frequency of miniature postsynaptic currents (mIPSCs), all of which indicate decreased 
presynaptic release probability. A presynaptic expression and a postsynaptic induction 
suggest an involvement of a retrograde signal. Indeed, we showed that the BDNF effect 
is blocked by CB1R antagonists or an eCB transport inhibitor. The DAG lipase inhibitors, 
THL and RHC-80627 also blocked the effect of BDNF, indicating that the BDNF induces 
the synthesis of 2-AG. These results, taken together, indicate the BDNF causes the 
release of endogenous cannabinoids at layer 2/3 inhibitory synapses of somatosensory 
cortex (Lemtiri-Chlieh and Levine, 2010). Next, we determined that the phospholipase CƔ 
(PLC-Ɣ) signaling pathway is required by BDNF to release endogenous 
endocannabinoids at neocortical inhibitory synapses. We showed that the BDNF effect is 
completely abolished by broad-spectrum PLC inhibitors, U73122 and edelfosine. We also 
confirmed that the effect of BDNF on inhibitory transmission does not require protein 
kinase C (PKC), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase 
(PI3K) signaling nor mGluR signaling. These results indicate that BDNF triggers the 
release of eCBs via phospholipase CƔ (PLCƔ pathway) (Zhao and Levine, 2014). There 
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is growing evidence of cross talk between BDNF and endocannabinoid signaling; our lab 
is interested in understanding the functional relevance of BDNF-eCB interactions in 
regulating activity-dependent long term depression at inhibitory synapses (iLTD). We 
found that the theta burst stimulation (TBS) protocol can induce a form of eCB-mediated 
iLTD at inhibitory synapses that does not require mGluR signaling. However, this eCB-
mediated iLTD required endogenous BDNF and TrkB signaling as it is blocked by a TrkB 
receptor antagonist and also requires activation of DAG lipase (DAGL). Taken together, 
these results suggest that TBS can cause the release of endogenous BDNF, which 
triggers DAGL-dependent eCB release and cannabinoid receptor-dependent iLTD at 
layer 2/3 inhibitory synapses of somatosensory cortex (Zhao et al., 2015).  However, it is 
unclear if similar interactions occur between BDNF and eCBs at cortical excitatory 
synapses or in hippocampus.  
      
      The highest levels of expression of TrkB and CB1 receptors are present in layers 2/3 
and 5 of somatosensory cortex. In layer 5 excitatory synapses of somatosensory cortex, 
we have shown that BDNF can modulate glutamatergic transmission while the 
predominant effect of eCBs is to suppress glutamate release. This suggests that the net 
effect on glutamate release depends on the balance between BDNF and eCB influences. 
In the first part of the present study, we examine whether BDNF can cause the release of 
eCBs at layer 5 excitatory synapses. We hypothesize that BDNF induces eCB release at 
excitatory synapses which could have a mitigating or opposing effect on the direct 
presynaptic effects of BDNF.  
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     We use long-term potentiation paradigms to examine the functional relevance of 
BDNF-eCB interactions at layer 5 excitatory synapses. TBS, high frequency stimulation 
(HFS) and chemical induction protocols are known to induce various forms of long term 
potentiation at excitatory synapses. Interestingly, some forms of TBS and HFS can also 
trigger the release of endogenous BDNF. We hypothesize that these LTP paradigms can 
cause release of endogenous BDNF. Released BDNF can activate postsynaptic TrkB 
receptors which then induces the release of eCBs and further leads to eCB-dependent 
forms of LTP. Our goal in this study is to identify paradigms that can cause LTP/LTD at 
layer 5 excitatory synapses and the involvement of BDNF and eCB signaling in the 
LTP/LTD paradigms.  
      
     Finally, the last part of the study focuses on understanding the interactions between 
BDNF and eCBs in CA1 inhibitory synapses of hippocampus. In hippocampal cells, acute 
application of BDNF causes a reduction in IPSCs and the effect is mediated by 
postsynaptic TrkB receptor activation  (Cheng and Yeh, 2003; Frerking et al., 1998; 
Lemtiri-Chlieh and Levine, 2010; Levine et al., 1995). The suppressive effect of BDNF on 
IPSCs is expressed presynaptically in the hippocampal CA1 region (Frerking et al., 1998) 
whereas several other studies indicate a postsynaptic involvement of TrkB receptors 
(Hewitt and Bains, 2006; Tanaka et al., 1997). The mechanisms that are involved in 
mediating the effects of BDNF are unknown. We hypothesize that BDNF mediates its 
effect via endocannabinoids which causes a suppression in inhibitory neurotransmission 
at CA1 inhibitory synapses of hippocampus.  
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     The studies presented in this dissertation examined: 1) the interactions between BDNF 
and eCBs at cortical excitatory synapses and their functional relevance in the context of 
long term synaptic plasticity; and 2) the interactions between BDNF and eCBs at 
hippocampal inhibitory synapses. Understanding the physiological role of BDNF and 
eCBs interactions at different brain regions will help us in elucidating the modulation of 
cortical and hippocampal circuitry. Further, both neuromodulators are widely implicated 
in an overlapping set of neurological and psychiatric disorders, a better and refined 
understanding of these interactions may help in uncovering the therapeutic strategies for 
disease treatments. The results of the present studies will be presented in chapters 2 and 
3 and will be discussed in Chapter 4.  
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Chapter 2 
BDNF-endocannabinoid interactions at cortical excitatory synapses 
 
Part of the work in this chapter (including Figures 2.1 and 2.2) is taken from Yeh ML, 
Selvam R and Levine ES, “BDNF-induced endocannabinoid release modulates 
neocortical glutamatergic neurotransmission” Synapse 2017: 71 (5).   
 
For that manuscript, M.L.Y. and E.S.L. were responsible for conception and design of 
research; M.L.Y. and R.S. performed experiments and analyzed data; M.L.Y. drafted the 
manuscript and all authors edited and revised the manuscript. 
The remainder of the work presented in this chapter is in progress and unpublished data 
carried out by R.S.  
 
2.1 Introduction 
     In the central nervous system, synapses are specialized sites of cell-to cell contact 
that form the basic substrate of information transfer within neuronal networks. Chemical 
neurotransmission, be it excitatory or inhibitory, is regulated by a range of 
neuromodulators. It is now widely accepted that the proper and precise modulation of 
synapses is critical for brain development as well as many cognitive functions in the adult. 
In the mammalian neocortex, the endocannabinoid (eCB) system and neurotrophin 
signaling pathways have both been well characterized and identified as important 
regulators of synaptic activity and neurotransmitter release. Extensive research within the 
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past decade has firmly established the role of eCBs as retrograde messengers 
suppressing neurotransmitter release in either a transient or long-lasting manner at both 
inhibitory and excitatory terminals (Alger, 2012; Chevaleyre et al., 2006; Freund and 
Hajos, 2003; Kano et al., 2009). Additionally, the eCB signaling system is now recognized 
as a regulator of various neural functions, including cognition, motor control, feeding 
behaviors and pain (Hillard et al., 2012; Mechoulam and Parker, 2013). Further, the 
dysregulation of the eCB signaling system has been implicated in neuropsychiatric 
disorders such as depression and anxiety, providing a clear and understudied 
experimental model for potential therapeutic interventions. Likewise, neurotrophins, 
specifically brain-derived neurotrophic factor (BDNF), have been shown to modulate the 
efficacy of synaptic transmission and their expression at the synapse is activity dependent 
(Berninger and Poo, 1996; Katz and Shatz, 1996; Minichiello, 2009; Park and Poo, 2013). 
Interestingly, multiple reports have described evidence for cross-talk between 
neurotrophin and eCB signaling. Specifically, (Zhong et al., 2015) showed that BDNF in 
midbrain dopamine neurons regulates eCB responses, cocaine-induced synaptic 
plasticity, and associative learning by selectively knocking down BDNF expression in 
dopaminergic neurons. In the visual cortex, BDNF has been shown to oppose eCB-
mediated forms of heterosynaptic long-term depression (LTD) at activated synapses by 
inducing homosynaptic long term potentiation (Huang et al., 2008). Furthermore, there is 
evidence of BDNF and its involvement as a modulator of eCB-mediated synaptic plasticity 
in the hippocampus (Roloff et al., 2010). Lastly, BDNF and eCB interactions have been 
demonstrated in mediating neuronal survival and protection against excitotoxicity 
(Khaspekov et al., 2004; Maison et al., 2009). 
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     BDNF may also be an important trigger for eCB synthesis and release. It is well 
established that eCB mobilization can be triggered by increases in intracellular calcium 
or activation of Gq coupled receptors and subsequent phospholipase C (PLC)-dependent 
increase in diacylglycerol (DAG), the precursor to 2-arachidonoylglycerol (2-AG) (Castillo 
et al., 2012; Hashimotodani et al., 2007a). In addition, we have recently shown that 
BDNF/TrkB signaling also triggers PLC-dependent eCB release. BDNF, acting through 
postsynaptic TrkB receptors, induces 2-AG release from pyramidal neurons at neocortical 
inhibitory synapses, which in turn suppresses GABA release from presynaptic terminals 
(Lemtiri-Chlieh and Levine, 2010; Zhao and Levine, 2014). In fact, the suppressive effect 
of BDNF seems to be completely mediated by eCBs, because the effect of BDNF at these 
inhibitory synapses is completely prevented by blocking cannabinoid type 1 (CB1) 
receptors or interfering with eCB synthesis or release. Furthermore, we also showed that 
theta burst stimulation induced release of endogenous BDNF can also trigger eCB 
synthesis and release resulting in inhibitory long-term depression (iLTD) (Zhao et al., 
2015). 
 
    In the present studies, we addressed two questions: (1) Whether BDNF can trigger the 
release of eCBs at excitatory synapses. It is known that BDNF can directly potentiate 
glutamatergic neurotransmission by enhancing presynaptic release probability 
(Carmignoto et al., 1997; Lessmann and Heumann, 1998; Li et al., 1998; Schinder and 
Poo, 2000; Tyler and Pozzo-Miller, 2003), as well as enhancing postsynaptic NMDA 
receptor responsiveness (Crozier et al., 1999; Levine et al., 1998; Lin et al., 1998; Madara 
and Levine, 2008). Conversely, eCB signaling decreases release probability at synapses 
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throughout the neocortex. However, it is not known if BDNF induces eCB release at 
excitatory synapses. We hypothesized that, if it occurs, BDNF-induced eCB release at 
excitatory synapses would act to mitigate the direct effects of BDNF. (2) Examine the 
functional interactions between BDNF and eCBs in long-term potentiation/long-term 
depression (LTP/LTD) at layer 5 excitatory synapses. Endogenous BDNF has been 
shown to play an important role in LTP while eCBs play a major role in mediating LTD. 
The patterns of activity used to induce these opposite forms of plasticity, however, likely 
cause the release of both eCBs and BDNF. We hypothesize that the direction of plasticity 
(potentiation or depression) induced by a given pattern of activity/stimulation depends on 
the relative levels of BDNF and eCBs that are released. In particular, we hypothesized 
that endogenous BDNF and eCBs can act opposing to each other to mediate LTP and/or 
LTD.  
 
2.2 Materials and methods 
1. Animal handling and slice preparation 
All animal procedures were conducted using protocols approved by the University of 
Connecticut Institutional Animal Care and Use Committee. Postnatal Day 15–27 Swiss 
CD1 (Charles River, Wilmington, MA) and C57BL/6J (The Jackson Laboratory, Bar 
Harbor, ME) mice were anesthetized by 3.5% isoflurane inhalation, followed by 
decapitation. Experiments were conducted on Swiss CD-1 mice except where noted. 
Whole brains were removed and immersed in ice-cold slicing solution containing (in mM) 
110 choline chloride, 2.5 KCl, 1.25 NaH2PO4-H2O, 25 NaHCO3, 0.5 CaCl2, 7 MgCl2-6H2O, 
25 D-glucose, 11.6 sodium ascorbate, and 3.1 sodium pyruvate, equilibrated with 95% 
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O2-5% CO2 (pH 7.3, 310±5 mosmol/kg). Transverse slices (300 µm) containing 
somatosensory cortex were cut with a Dosaka EM DTK-1000 vibratome (Kyoto, Japan) 
and transferred to an incubating chamber. Slices were then incubated for 15 min at 33–
35ºC in carboxygenated incubating solution containing (in mM) 125 NaCl, 2.5 KCl, 1.25 
NaH2PO4- H2O, 25 NaHCO3, 0.5 CaCl2, 3.5 MgCl2-6H2O, 25 D-glucose, 4 sodium lactate, 
2 sodium pyruvate, and 0.4 ascorbic acid (pH 7.3, 310±5 mosmol/kg) before being 
transferred to room temperature. Slices were then individually transferred to a recording 
chamber (room temperature) fixed to the stage of an Olympus BX51WI upright 
microscope fitted with an x40 water-immersion objective lens (0.8 NA). The recording 
chamber was continuously perfused at 1.5–2.0 ml/min with carboxygenated artificial 
cerebrospinal fluid (aCSF) consisting of (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH2PO4-H2O, 
25 NaHCO3, 2 CaCl2, 2 MgCl2-6H2O, and 25 D-glucose (pH 7.3, 305±5 mosmol/kg).  
 
2. Electrophysiology 
Whole cell recordings were obtained from layer 5 somatosensory cortex pyramidal 
neurons. Neurons were visually identified by their morphology and position under infrared 
differential interference contrast video microscopy. Patch electrodes (2–4 MX) were 
pulled from borosilicate glass capillaries using a Flaming/Brown P-97 micropipette puller 
(Sutter Instrument, Novato, CA). Pipette internal solution contained (in mM) 4 KCl, 125 
K-Gluconate, 10 HEPES, 10 Phosphocreatine, 1 EGTA, 0.20 CaCl2, 4 Na2-ATP, and 0.30 
Na-GTP. The sodium equilibrium potential (ENa) with the use of the above internal and 
external solutions was close to +90 mV; thus EPSCs were recorded as inward currents. 
Cells were voltage clamped at -70 mV during recording. Miniature excitatory postsynaptic 
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currents (mEPSCs) were isolated by bath perfusion of tetrodotoxin (TTX, 500 nM). 
Spontaneous excitatory postsynaptic currents (sEPSCs) were isolated without TTX. 
 
A bipolar tungsten electrode (1 MΩ; WPI; Sarasota, FL) was positioned 70-150 µm 
intralaminarly to the patched pyramidal neuron to elicit electrically evoked excitatory 
postsynaptic currents (eEPSCs). Extracellular stimuli consisted of individual square wave 
current pulses (170 µs; 4-30 µA) and were delivered every 20 secs through an ISO-flex 
stimulus isolator (Jersualem, Israel). Every third evoked response will be delivered using 
a paired pulse protocol with a 75 ms interpulse interval.  Stimulation strength was set to 
a level that evoked 30-70% of maximal response of each individual cell. For recording 
sEPSCs and eEPSCs, we used a pipette internal solution containing (in mM): 130 CsCl, 
10 HEPES, 1 EGTA, 0.1 CaCl2, 1.5 MgCl2, 4 Na2-ATP, 0.3 Na-GTP, 10 
phosphocreatinine and 5 QX-314 (pH 7.3, 290 ± 5 mOsm/kg).  
 
All electrical currents were filtered at 2.9 kHz and digitized at >6 kHz using a HEKA EPC9 
amplifier and ITC-16 digitizer (HEKA Elektronik, Darmstadt, Germany). Series resistance 
(Rs) was compensated up to 50% at 10–100 ls lag. Input resistance (Ri) was monitored 
with 10 mV (50 ms) hyperpolarizing voltage steps at the end of each sweep. Cells were 
rejected from analyses if Ri changed by>15% or fell below 50 MΩ during the course of an 
experiment. 
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3. Chemicals 
Unless otherwise stated, all drugs were obtained from Tocris Biosciences (Bristol, UK) 
and were delivered by bath perfusion. Drugs were first prepared as concentrated stock 
solution in solvents and stored at -20°C. Stock solutions of WIN55-212,2, ANA-12, 
SR141716A, AM404, K252a, forskolin and DHPG were dissolved in 100% dimethyl 
sulfoxide (DMSO). The stock solution of BDNF, rolipram and cyclotraxin-B (CTX-B) was 
dissolved in 18 MΩ water. The stock solution of TTX was dissolved in aCSF. Drug stock 
solutions were diluted in aCSF on the day of recording to the final concentrations. The 
final concentration of DMSO did not exceed 0.1%, which by itself had no effect on synaptic 
transmission.  
 
4. Data analysis 
Off-line analysis of whole-cell patch clamp electrophysiological recordings was carried 
out using Clampfit 10 (Molecular Devices, Sunnyvale, CA) and Prism 6 (GraphPad 
Software, La Jolla, CA). Group data are reported as means±SE. Statistical comparisons 
were made using one-way ANOVA and Dunnett’s multiple comparison test or paired 
Student’s t test for post hoc comparison. p <.05 was taken as a statistically significant 
effect. 
 
2.3. Results 
2.3.1 Effect of BDNF on spontaneous release probability at excitatory synapses 
     We first confirmed that CB1 and TrkB receptors are colocalized in layer 5 excitatory 
synapses of somatosensory cortex. Then, we examined the effect of exogenous BDNF 
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(20 ng/ml, 0.8 nM) on isolated AMPA-mediated mEPSCs in layer 5 of mouse 
somatosensory cortex. As illustrated by sample traces and group data in Figure 2.1a, 
bath application of 20 ng/ml BDNF (0.8 nM) had no significant effect on mEPSC 
frequency. The amplitude of mEPSCs was also not affected by bath-applied BDNF in any 
cells sampled (Figure 2.1a bottom). A higher concentration of BDNF (50 ng/ml, 2.0 nM) 
also failed to alter mEPSC frequency or amplitude in layer 5 of somatosensory cortex 
(Figure 2.1b). In light of the negative results obtained with BDNF in layer 5 of 
somatosensory cortex, we also examined the effect of BDNF in areas where it had been 
previously shown to increase mESPC frequency, including layer 5 of visual cortex 
(Madara and Levine, 2008), and hippocampus (Alder et al., 2005; Gibon et al., 2016; Leal 
et al., 2015). In contrast to the lack of effect in layer 5 of somatosensory cortex, BDNF 
(0.8 nM) increased mEPSC frequency in hippocampal CA1 PNs (ANOVA (F)14,74=2.75, 
p<.05; Baseline, 6.6361.83 Hz; BDNF, 7.87±2.01, n=7 cells, 2 animals) (Figure 2.1c) and 
in layer 5 PNs of visual cortex (ANOVA (F)14,73=1.86, p<.05; Baseline, 2.05±0.88 Hz; 
BDNF, 2.54±0.83, n=6 cells, 2 animals) (Figure 2.1d). As expected, BDNF did not 
enhance the amplitude of AMPA-mediated mEPSCs in these areas (Figure 2.1c,d). 
Lastly, we confirmed the role of BDNF/TrkB signaling in mediating the increase in mEPSC 
frequency in both CA1 of hippocampus and layer 5 of visual cortex by bath-applying 
BDNF in the presence of the TrkB receptor specific antagonist, ANA-12 (10 µM) (Figure 
2.1c,d). We did not observe any effect of ANA-12 alone on mEPSC frequency or 
amplitude. Furthermore, ANA-12 blocked the increase in mEPSC frequency elicited by 
exogenous BDNF (2.0 nM) application in the CA1 of hippocampus and layer 5 of visual 
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cortex (Figure 2.1c,d). The effect of BDNF and its block by ANA-12 were seen in both 
CD1 and C57 mice, thus data from the two strains were pooled for the above analysis.  
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Figure 2.1: BDNF has region-specific effects at cortical excitatory synapses. (a) Group 
time courses showing lack of effect of 0.8 nM BDNF on mEPSC frequency (top) and 
amplitude (bottom) in layer 5 pyramidal neurons of somatosensory cortex (n=14 cells; 5 
animals). Insets, in this and following panels, show sample traces during baseline and in the 
presence of BDNF from a representative experiment. Scale bars in all sample traces are 10 
pA, 100 ms. (b) Similar lack of effect of 2.0 nM BDNF on mEPSC frequency (top) and 
amplitude (bottom) in layer 5 of somatosensory cortex (n=12 cells; 3 animals). (c) Effect of 
BDNF (0.8 nM) on mEPSC frequency and amplitude in CA1 hippocampal pyramidal cells 
(n=7 cells; 2 animals—1 CD1, 1 C57). Data from individual experiments compare mEPSC 
frequency during minutes 3–5 of BDNF exposure to baseline. Bottom graph, effect of BDNF 
on mEPSC frequency is blocked in the presence of the TrkB receptor antagonist, ANA12 (10 
µM; n=4 cells; 1 CD1, 1 C57). (d) Effect of BDNF (0.8 nM) on mEPSC frequency and 
amplitude in layer 5 of visual cortex (n=6 cells; 1 CD1, 1 C57). Data from individual 
experiments compare mEPSC frequency during minutes 3–5 of BDNF exposure to baseline. 
Bottom graph, effect of BDNF on mEPSC frequency is blocked in the presence of the TrkB 
receptor antagonist, ANA12 (10 µM; n=4 cells; 1 CD1, 1 C57). *p<.05 
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2.3.2. Endocannabinoid signaling opposes BDNF-mediated potentiation of 
excitatory neurotransmission 
     We hypothesized that the inability of BDNF to produce a net increase in mEPSC 
frequency in layer 5 somatosensory cortical neurons may be the result of BDNF-TrkB 
induced release of eCBs that have an opposing effect on presynaptic release probability. 
We first confirmed the effects of CB1 receptor activation at these excitatory synapses with 
the CB1 receptor agonist WIN 55,212–2 (WIN; 5 mm). Bath application of WIN decreased 
mEPSC frequency (Baseline 1.82±0.45 Hz; WIN 1.03±0.25 Hz; Student’s t test; n=8, 4 
animals) (Figure 2.2d) with no change in mEPSC amplitude. Because CB1 receptor 
signaling typically attenuates presynaptic release via inhibition of voltage-gated calcium 
channels (VGCCs) (Kreitzer and Regehr, 2001; Lozovaya et al., 2009; Szabo et al., 
2014), we examined the effect of WIN in the presence of cadmium (Cd2+; 100 µM) to 
block VGCCs. As shown in Figure 2.2d, bath application of Cd2+ alone reduced mEPSC 
frequency (Baseline 2.75±0.97 Hz; Cd2+ 1.18±0.48 Hz; Student’s t test, n=4, 1 animal). 
Subsequent addition of WIN in the presence of Cd2+ had no further effect on mEPSC 
frequency (Figure 2.2d). Taken together, these data indicate that VGCCs contribute to 
spontaneous glutamatergic release at these synapses, and that cannabinoid-mediated 
suppression of release requires VGCC activity, similar to what was reported for layer 2/3 
inhibitory synapses (Madara and Levine, 2008; Trettel and Levine, 2002)(Madara & 
Levine, 2008; Trettel & Levine, 2002). To test whether BDNF-induced eCB release was 
mitigating the direct effect of BDNF, we examined the effect of BDNF (0.8 nM) in the 
presence of the CB1 receptor-specific inverse agonist, SR141716A (SR; 10 mM) (Figure 
2). In this experiment, SR was bath-applied for 10 minutes, followed by a 10 min perfusion 
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of BDNF (0.8 nM) in the 
continued presence of SR. 
Representative traces from a 
single experiment are shown in 
Figure 2.2a. Application of SR 
resulted in a small but 
nonsignificant and transient 
increase in the frequency of 
mEPSCs in the majority of cells 
tested, as shown in the group 
data presented in Figure 2.2b. 
The amplitude of mEPSCs was 
not affected by SR alone (Figure 
2.2c). As shown in the group 
data presented in Figure 3b, 
exogenous BDNF (0.8 nM) 
application in the presence of 
SR resulted in a statistically 
significant increase in mEPSC 
frequency. mEPSC frequency 
was increased to 159.4%±13.5% at 5 min of BDNF exposure in the presence of SR 
(ANOVA (F)14,131=1.76, p<.05; SR 1.36 Hz±0.27; SR+BDNF 1.97 Hz±0.36; n=15, 5 
animals) (Figure 2.2b). We have shown that the direct effects of BDNF can be unmasked 
Figure 2.2: Blocking CB1 receptors unmasks BDNF-
induced potentiation in layer 5 somatosensory 
cortex pyramidal cells. (a) Sample sweeps of mEPSCs 
during baseline, in the presence of SR141716A (SR; 10 
µM) alone, and in the presence of SR plus BDNF (0.8 
nM). Scale bar 10 pA, 100 ms. (b) Group time course 
showing the effect of bath-applied SR (10 µM) on 
mEPSC frequency, followed by BDNF (0.8 nM) in the 
presence of SR. n=10 cells, 2 animals. (c) Group time 
course for the same cells as (c) showing no effect of SR 
alone or BDNF plus SR on mEPSC amplitude. *p<.05 
compared to SR alone. (d) Left, Cannabinoid agonist 
WIN55,212–2 (WIN; 5 µm) decreased mEPSC 
frequency (n=8 cells; 4 animals). Right, Blocking 
voltage-gated calcium channels with cadmium (Cd2+; 
100 µM) decreased mEPSC frequency, and prevented 
the effect of WIN (n=4 cells, 1 animal). *p<.05 
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either by blocking CB1 receptors or by inhibiting postsynaptic eCB release from pyramidal 
neurons. These results support our hypothesis that BDNF/TrkB signaling causes the 
release of eCBs at excitatory synapses, which directly opposes direct BDNF-mediated 
potentiation of glutamatergic release probability.  
 
2.3.3 Pharmacologically-induced long term potentiation (LTP) 
     A combination of forskolin, an adenylyl cyclase activator (50 µM) and rolipram, a 
phosphodiesterase inhibitor (0.1µM) in the presence of 0 Mg2+ (Otmakhov et al., 2004) 
was used to induce LTP at excitatory synapses onto layer 5 pyramidal neurons of 
somatosensory cortex. Forskolin/rolipram causes a stable increase in intracellular cAMP 
levels thereby activating protein kinase A and the removal of Mg2+ enhances NMDA 
receptor activation. We induced LTP by exposure to this induction cocktail for 10 or 15 
minutes. We examined frequency and amplitude of spontaneous excitatory postsynaptic 
currents (sEPSC) recorded from layer 5 pyramidal neurons.  As shown in figure 2.3a, this 
chemical induction protocol induced potentiation of excitatory transmission lasting ~40 
minutes. As shown in figure 2.3a, 10 minutes of forskolin/rolipram/0 Mg2+ exposure 
increased the frequency of spontaneous excitatory postsynaptic currents (ANOVA, 
F(6.84)= 29.57; p< 0.05; n=7; 3 animals). The induction paradigm did not have any 
significant effect on amplitude (Fig 2.3b) nor on the amplitude distribution (Fig 2.3c).  Next, 
we determined if the chemically-induced form of LTP can be potentiated with 15 minutes 
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of treatment. As shown in figure 2.3d, evoked EPSC amplitude (eEPSC) was potentiated 
in all 5 cells tested. In contrast to 10 minutes treatment, 15 minutes of treatment induced 
potentiation of excitatory transmission lasting for ~90 minutes (figure 2.3E). Similar to 10 
minutes treatment, the 15-minute treatment increased the frequency of spontaneous 
 
Figure 2.3: Long term potentiation at layer 5 excitatory synapses (A) Group time course 
for the sEPSC frequency and (B) sEPSC amplitude for the same neurons (n=7, 3 animals). 
Each data point is 10 minute average bins of frequency and/or amplitude. (C) Cumulative 
amplitude distribution of all neurons during baseline and 30 minutes post-induction. (D) Group 
time course of eEPSC amplitude with 15 minutes of forskolin exposure (n=5, 2 animals). (E) 
Group time course of sEPSC frequency and (F) sEPSC amplitude of 9 cells with 15 minutes 
of forskolin treatment. Pink color indicates 15 mins duration while black indicates 10 mins 
duration (for comparison). Arrow indicates the 10 or 15 minutes of forskolin induction. *p<0.05 
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excitatory postsynaptic currents (figure 2.3E) but not amplitude of sEPSCs (Figure 2.3F; 
n=8, 2 animals).   
 
2.3.4 Excitatory LTP is independent of BDNF signaling 
     Because many forms of LTP require endogenous BDNF signaling, we examined the 
effects of the chemical induction protocol during bath application of TrkB receptor 
antagonists. We hypothesized that the chemical induction protocol causes the release of 
endogenous BDNF.  We used three TrkB receptors antagonists to test the effects on both 
10 minutes and 15 minutes of chemical induction – (1) K252a (200 nM), tyrosine kinase 
inhibitor that inhibits TrkB at lower concentrations (Lemtiri-Chlieh and Levine, 2010; Zhao 
and Levine, 2014); (2) ANA12 (5 µM) , a TrkB selective non-competitive antagonist (Zhao 
et al., 2015) and (3) Cyclotraxin B (10 µM), a TrkB selective non-competitive antagonist 
(Maglio et al., 2018; Zhao et al., 2015).  As shown in figures 2.4 and 2.5, blocking BDNF 
signaling did not prevent the induction of LTP at layer 5 excitatory synapses. If 
endogenous BDNF is involved in the paradigm, we expected to see a decrease in the 
frequeuncy of sEPSCs in the presence of TrkB receptor antagonists.  As shown in figure 
2.4a, c, e, 10 minutes of forskolin/rolipram/ 0 Mg2+ treatment in the presence of TrkB 
receptor antagonists had no change in the sEPSC frequency compared to 
forskolin/rolipram/ 0 Mg2+ treatment alone.  The amplitude of sEPSCs was not affected 
by the forskolin/rolipram/ 0 Mg2+ treatment in the presence of TrkB receptor antagonists 
(Fig 2.4b, d, f).  Similarly, 15 minutes of forskolin/rolipram/ 0 Mg2+ treatment in the 
presence of TrkB receptor antagonists had no change in the sEPSC frequency (fig 2.5).  
With both 10 and 15 minutes of forskolin/rolipram/ 0 Mg2+ treatment, the amplitude of 
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sEPSCs had no effect. This result led to three conclusions: (1) BDNF is not released in 
this induction paradigm or (2) The effect of endogenous BDNF is masked by effect of 
eCBs in sEPSC frequency similar to the lack of exogenous BDNF effect in mEPSC 
frequency observed and reported in layer V excitatory synapses or (3) The combination 
of forskolin and rolipram causes a very strong stimulation that it activates several 
downstream signaling molecules and pathways causing a ceiling effect. Hence, even if 
 
Figure 2.4: Excitatory LTP is independent of BDNF signaling with 10 minutes of 
forskolin/rolipram treatment (A) Group time course of sEPSC frequency and (B) sEPSC 
amplitude in the presence of K252a (n=12; 4 animals). (C) Group time course of sEPSC frequency 
and (D) sEPSC amplitude in the presence of ANA-12 (n=7; 2 animals). (E) Group time course of 
sEPSC frequency and (F) sEPSC amplitude in the presence of cyclotraxin-B (CTX-B; n=8; 2 
animals). Arrow indicates 10 minutes of forskolin treatment. Black data points in all graphs are 
from controls (from figure 2.3a, 2.3b). 
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BDNF is released here, BDNF 
does not affect the 
effectiveness of the LTP 
stimulation as the stimulation 
from forskolin/rolipram is much 
stronger than BDNF alone. 
 
2.3.5. Excitatory LTP is 
independent of 
endocannabinoid signaling 
     Assuming that there is an 
involvement of endogenous 
eCBs in excitatory synapses, 
we hypothesized that by 
blocking CB1 receptors we 
expect to see an increase in 
sEPSC frequency and 
amplitude in the induction 
protocol. However, as shown 
in figure 2.6, we did not see 
any change in sEPSC frequency and amplitude in the presence of CB1 receptor 
antagonist (SR141716A; 10µM). This led to conclusion that neither BDNF nor 
endocannabinoids are involved in this pharmacologically-induced form of LTP.  
 
Figure 2.5: Excitatory LTP is independent of BDNF 
signaling with 15 minutes of forskolin/rolipram 
treatment (A) Group time course of sEPSC frequency in the 
presence of K252a (n=2; 1 animal). (B) Group time course of 
sEPSC frequency in the presence of ANA-12 (n=1; 1 
animals). (C) Group time course of sEPSC frequency in the 
presence of cyclotraxin-B (CTX-B; n=2; 1 animal). Arrow 
indicates 15 minutes of forskolin treatment. Pink data points 
in all graphs are from controls (from figure 2.3e). 
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2.3.6 Electrically induced forms of 
LTP 
     Similar to other brain areas including 
hippocampus, striatum, amgydala and 
visual cortex, we used electrically 
induced protocols to elicit LTP at layer 5 
synapses as opposed to chemical 
stimulation. The available induction 
paradigms in literature are: high 
frequency stimulation (HFS), theta burst 
stimulation (TBS), pairing protocols 
(PP). Nevertheless, I was not able to 
elicit a LTP with any of the paradigms 
which could be partly due to the inability to recapitulate the required circuitry, stimulation 
patterns of where and how to stimulate in this brain region. Below is the table summarizing 
the induction protocols and the stimulation pattern that have been used: 
Induction 
Protocol 
Stimulation paradigm Position 
of 
electrode 
in layer  
Brain region 
reported in 
literature  
TBS 7X TBS delivered with a 5s intertrain interval.  
Each TBS train contained 10 bursts (200ms 
interburst interval), each burst consisted of 5 
stimuli at 100Hz. 
5, 2/3 Somatosensory 
cortex (Zhao 
and Levine, 
2014) 
HFS 25 pulses given at 100Hz 5 Hippocampus(
Wang et al., 
1997) 
TBS 3X TBS delivered with a 5s intertrain interval.  
Each TBS train contained 10 bursts (200ms 
5, 2/3 Hippocampus 
(Aarse et al., 
2016) 
 
Figure 2.6: Excitatory LTP is independent of 
eCB signaling (A) Group time course of sEPSC 
frequency and (B) sEPSC amplitude in the 
presence of SR (n=5; 2 animals). Arrow 
indicates 10 minutes of forskolin treatment. 
Black data points in all graphs are from controls 
(from figure 2.3a, b). 
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interburst interval), each burst consisted of 4 
stimuli at 100Hz. 
TBS 10X TBS delivered with a 10s intertrain 
interval. Each episode of TBS contained 20 
bursts at 5 Hz, each burst containing five 
pulses at 100 Hz. One cell out of 12 cells in 
this experiment showed LTP 
5 Layers II/III/V of 
sensorimotor 
cortex (Chen et 
al., 2009)  
HFS Two trains of 50 pulses at 100Hz (HFS) given 
at 5 min intervals 
5 Hippocampus 
(Aarse et al., 
2016) 
TBS 10 bursts of four pulses given at 100Hz, in 
the form of one train 
5,4 Hippocampus(A
arse et al., 2016) 
HFS 50 Hz, 1 s was applied 10 times at intervals 
of 10 s 
4 Layer V of visual 
cortex (Inagaki 
et al., 2008) 
HFS 100 Hz, 1 s was applied 4 times at 10 s 
intervals 
5, 2/3 Medium spiny 
neurons in 
striatum, 
hippocampus 
(Jia et al., 2010) 
Pairing 
protocol 
4 brief high frequency tetani (50 pulses at 50 
Hz; 4 s intervals) paired with a short 
depolarization of 15s 
5 Hippocampus 
(Wang et al., 
1997) 
Pairing 
protocol 
4 brief high frequency tetani (50 pulses of 50 
Hz; 4s intervals) paried with a long 
depolarization of 3 minutes 
5 Hippocampus 
(Wang et al., 
1997) 
Pairing 
protocol 
Low frequency protocol (200 pulses, 1.4Hz) 
paired with long depolarization of 3 minutes 
5 Hippocampus(
Wang et al., 
1997) 
Pairing 
protocol 
3X TBS delivered at 30 s intervals.  Each 
TBS consists of 5 bursts each consisting of 4 
stimuli at 100 Hz with a 250 ms interburst 
interval. TBS was paired with postsynaptic 
depolarization (5 depolarizing steps to -20 
mV, 60 ms long).  Repeated this paradigm 
with 7 trains and 10 trains of TBS yet did not 
observe LTP. 
5  Hippocampus(L
apointe et al., 
2004) 
Pairing 
protocol 
Stimulation protocol consisted of presynaptic 
activation of 10 bursts, each bursts with 5 
pulses at 100Hz, spaced at 200ms, repeated 
3 times at 10s intervals and postsynaptic 
injection of a depolarizing current pulse (1.5 
nA, 40 ms) during each burst, with a 5ms 
interval between the onset of pre- and 
postsynaptic stimulation. This protocol works 
5  Medial 
Prefrontal 
cortex(Lu et al., 
2010) 
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on medial prefrontal cortex in my 
experimental setup. 
 
2.3.7. Chemical induction by DHPG induces LTD 
     Using a chemical 
induction paradigm 
(Izumi and Zorumski, 
2012; Peterfi et al., 
2012), we examined 
LTD at excitatory 
synapses of layer 5 
pyramidal neurons of 
somatosensory 
cortex. Induction 
paradigm consisted 
of DHPG application 
to slices for 10 
minutes to induce 
plasticity. Cells were then perfused with ACSF and held for 90 mins post-induction. 
sEPSC amplitude and frequency were measured. Example traces of baseline, DHPG 
application and 30 minutes post induction were shown in Figure 2.7a. As shown in figure 
2.7b and 2.7c, bath application of DHPG (50 µM) decreased the amplitude but not the 
frequency of spontaneous excitatory postsynaptic currents (n=3 cells, 3 animals). As 
shown in figure 2.8 DHPG also decreased the amplitude of evoked responses (eEPSC) 
 
Figure 2.7: Long-term depression of spontaneous excitatory 
activity in pyramidal neurons (A) Sample traces of sEPSCs. Scale 
bar: 50 pA, 5 s. (B) Time course of sEPSC amplitude. (C) Time 
course of sEPSC frequency for the same neurons.  (n=3 cells from 
3 animals). 
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and increased the paired 
pulse ratio (PPR), a measure 
of release probability. 
Example traces and 
individual cells during 
baseline, DHPG application 
and post-induction period 
were shown in figure 2.8a.  
Group data showed that the 
eEPSC amplitude 
decreased during and 90 
minutes after DHPG 
treatments to 75% and 74% 
of eEPSC amplitude before 
exposure respectively (Fig 
2.8b). Similarly, group data 
of all cells showed an increase in PPR during and 90 minutes after DHPG treatment (Fig 
2.8c) indicating that the expression of LTD includes a presynaptic component in this 
paradigm (n=3 cells, 3 animals).  This form of chemically induced LTD can be used to test 
the involvement of BDNF and eCBs at these synapses.  
 
 
 
 
 
Figure 2.8: Long-term depression of evoked responses 
in pyramidal neurons (A) Top: Sample sweeps of eEPSCs 
application during baseline (1), DHPG (2), 30(3), 60 (4) and 
90minutes (5) post-DHPG. Scale bar: 200 pA, 20 ms. 
Bottom: An example time course of eEPSC amplitude 
showing LTD at 30, 60 and 90 minutes (circles). Increase in 
paired pulse ratio (stars) of a single pyramidal cell is also 
shown during the same time course. (B) Group data showing 
a decrease in eEPSC amplitude during and at 90 minutes 
post-DHPG application. (C) Paired pulse ratio showing an 
increase with DHPG and 90 minutes indicating that the LTD 
observed here is presynaptic in expression. (n=3 /3 
animals). 
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2.3.8 Electrical stimulation-induced LTD 
     Using low 
frequency 
stimulation (LFS), we 
examined LTD at 
layer 5 pyramidal 
neurons of 
somatosensory 
cortex. Stimulation 
consisted of 900 
pulses at 1Hz (Izumi 
and Zorumski, 2012).  
This protocol 
induced a stable 
long-lasting 
suppression of 
excitatory 
transmission. Figure 
2.9a shows the 
sample traces and an example time course of a cell showing a decrease in eEPSC 
amplitude after LFS and no change in PPR.  Group data showed a significant decrease 
in eEPSC amplitude at 30 and 60 minutes post induction (Fig 2.9b; ANOVA, F(2,9)= 17.14; 
p<0.05. BL: 1053 ± 72.11 pA; 30 minutes: 494.3 ± 35.56 pA; 60 minutes: 496 ± 107.7 
 
Figure 2.9: Induction of LTD by low frequency stimulation (LFS). 
(A) Top: Example sweeps of eEPSC amplitude during baseline, 30 
and 60 mins post LFS. Scale bar: 200 pA, 100 ms. Bottom: An 
example layer V pyramidal cell (pink circles) showing LTD after LFS 
protocol (900 pulses at 1 Hz) and no change in paired pulse ratio 
(purple stars). (B) Group data showing a significant decrease in 
eEPSC amplitude at 30 and 60 mins post LFS (C) No change in paired 
pulse ratio suggests that the LFS-induced LTD is expressed 
postsynaptically (n=4/1 animal). *p<0.05 
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pA). No change observed in PPR suggests that LTD has a postsynaptic component in 
the LFS paradigm (fig 2.9c). These results indicate that LTD can be obtained consistently 
in acute slices with both paradigms and the magnitude of duration of LTD is 90 minutes. 
We can now use these LTD paradigms to examine the role of endogenous BDNF and/or 
endogenous cannabinoids in mediating these forms of plasticity.  
 
2. 4  Discussion 
     We recently showed that BDNF induces release of eCBs from postsynaptic pyramidal 
cells in layers 2/3 of somatosensory cortex (Lemtiri-Chlieh and Levine, 2010). This effect 
of BDNF is initiated by postsynaptic TrkB signaling, requires downstream phospholipase-
CƔ (PLCƔ) signaling and is independent of metabotropic glutamate receptor (mGluR) 
activation (Zhao and Levine, 2014). Furthermore, we established a role for endogenous 
BDNF in eCB-mediated plasticity at cortical inhibitory synapses, where strong theta burst 
stimulation (TBS) in layers 2/3 of somatosensory cortex can induce iLTD that requires 
BDNF-TrkB and diacylglycerol (DAG) signaling (Zhao et al., 2015). To complement these 
studies of BDNF and eCB interactions at cortical inhibitory synapses, we asked whether 
BDNF also triggers the release of eCBs at cortical excitatory synapses. We have shown 
that BDNF and eCBs exert opposing effects at cortical excitatory synapses (Fortin and 
Levine, 2007; Madara and Levine, 2008). However, whether these two distinct signaling 
systems interact and the net functional outcome of these influences at excitatory 
synapses remains unexplored. We then examined the synaptic effects of eCB-CB1 
receptor signaling and BDNF-TrkB receptor signaling on spontaneous transmission at 
excitatory terminals within layer 5 of the somatosensory cortex. Surprisingly, we found 
that BDNF by itself did not increase mEPSC frequency (or amplitude) at these synapses. 
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To confirm previous reports of BDNF effects on mEPSC frequency in other brain regions 
(Carmignoto et al., 1997; Li et al., 1998; Schinder and Poo, 2000; Tyler and Pozzo-Miller, 
2003), we examined the effect of BDNF in pyramidal neurons in the hippocampal CA1 
region and layer 5 of visual cortex. We found that BDNF significantly increased mEPSC 
frequency in these regions, these effects were blocked by a TrkB receptor antagonist, 
and these effectts were consistent across two different mouse strains. 
 
     We next determined whether a BDNF-induced release of eCBs at excitatory synapses 
in layer 5 of somatosensory cortex might offset the direct presynaptic effects of BDNF. 
Blocking eCB signaling with a CB1 receptor antagonist unmasked a BDNF-induced 
increase in mEPSC frequency. Blocking postsynaptic release of eCBs had a similar 
effect. These results suggest that BDNF-TrkB signaling induces the release of eCBs at 
excitatory synapses. While our group and others have previously described an increase 
in presynaptic release probability as a result of acute BDNF exposure in other brain 
regions, this is the first study examining synaptic effects of BDNF in layer 5 of mouse 
somatosensory cortex. In this region, we find that BDNF activates presynaptic TrkB 
receptors to enhance spontaneous release probability, while simultaneously triggering 
the postsynaptic release of eCBs that act to decrease release via presynaptic CB1 
receptors. The presynaptic effects of BDNF on spontaneous glutamate transmission may 
have functional consequences of their own (Carmignoto et al., 1997) (Lessmann and 
Heumann, 1998) (Schinder and Poo, 2000; Tyler and Pozzo-Miller, 2003) and may also 
translate to changes in evoked AP-dependent release. However, there is a lack of clear 
evidence for effects of BDNF on evoked glutamate release. This may in fact reflect the 
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offsetting effect of BDNF-induced eCB release, and/or the effects of BDNF on evoked 
release may depend on specific AP activity patterns. It is also important to recognize that 
evoked (action potential-dependent) and spontaneous (action potential-independent) 
neurotransmitter release may utilize distinct vesicle pools that can be differentially 
regulated ((Huntwork and Littleton, 2007; Littleton et al., 1993; Maximov et al., 2007; Pang 
et al., 2011; Yoshihara et al., 1999). Furthermore, nonoverlapping populations of 
postsynaptic NMDA receptors have been implicated in differentiating between 
spontaneous and evoked release (Atasoy et al., 2008; Melom et al., 2013).      
 
     In summary, our published study contributes to uncovering region-specific roles of the 
eCB-CB1 receptor and BDNF-TrkB receptor signaling pathways at cortical excitatory 
synapses. Moreover, we provide evidence that BDNF-TrkB signaling may play an 
important role in triggering eCB release at cortical excitatory synapses. These two 
signaling systems have been implicated in various neurological disease states, including 
autism spectrum disorders, schizophrenia and epilepsy. There is, at present, a 
continuously growing body of evidence that the eCB system and BDNF system interact 
at various levels across multiple fields, including synaptic plasticity (De Chiara et al., 
2010; Maison et al., 2009), neuropathic pain (Luongo et al., 2014), cortical development 
(Berghuis et al., 2005; Galve-Roperh et al., 2013) and neuroprotection in depression and 
epileptic seizures (Aguado et al., 2007; Aso et al., 2008; Khaspekov et al., 2004; 
Marsicano et al., 2003; Vinod et al., 2012). Careful examination and elucidation of these 
interactions at excitatory and inhibitory synapses will be essential to the development and 
implementation of novel and effective therapeutic strategies. 
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      In the context of understanding the interactions between BDNF and eCBs, the second 
part of the chapter focused on long term plasticity and how these two neuromodulators 
interact.  We first determined the chemical induction paradigms to induce LTP at 
excitatory synapses of somatosensory cortex. Compared to 10 minutes induction 
paradigm, 15 minutes induction paradigm caused a longer lasting potentiation of 
excitatory transmission (~ 90 minutes).  To test for the involvement of BDNF and eCBs in 
this paradigm, we used antagonists to block the relevant receptors. We concluded that 
neither endogenous BDNF nor eCBs were required to elucidate LTP in this paradigm. 
This result led to several conclusions – (i) the chemical induction paradigm of forskolin 
and rolipram may be too strong by itself, hence causing large increases in cAMP levels 
which makes the contribution of BDNF nor eCBs insignificant, if any. To this effect, we 
will perform a dose-response with different concentrations and/or duration of 
forskolin/rolipram/ 0 Mg2+ to determine the role of BDNF and/or eCBs in this system. (ii) 
BDNF contributes more to some forms of LTP than others and that pattern determines 
the dependence of resulting potentiation of BDNF. Maybe, in this paradigm, BDNF 
release is minimal compared to eCB release, hence, we do not see an effect of BDNF. 
To ascertain if there is an effect of eCBs at these synapses, we can perform DSE to 
determine eCB-mediated suppression (Fortin et al., 2004). Further, blocking CB1 
receptors did increase the magnitude of forskolin in 5 cells, obtaining additional cells 
might help us resolve this question. (iii) This chemical induction protocol is truly 
independent of BDNF signaling in this brain area. We will examine other induction 
paradigms that are dependent in BDNF (Abidin et al., 2006; Edelmann et al., 2015; Lu et 
al., 2010). We will also explore the same protocol in CA1 hippocampus to determine if 
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there is a region specificity. (iv) Increase in cAMP levels can cause the release of BDNF 
which in turn activates MAPK pathway (directly or through translocation of MAPK) 
downstream to potentiate at the synapses (Patterson et al., 2001). It will be interesting to 
find out whether BDNF can activate both MAPK pathway (to exert its effects on LTP) and 
PLC Ɣ signaling to trigger eCB release.  
       
     We also tested several electrical stimulation protocols to elicit LTP at layer 5 excitatory 
synapses. Despite my efforts, we could not obtain potentiation at these synapses. The 
lack of plasticity in this region could be for the following reasons: (i) inability to recapitulate 
the circuitry in our preparation. (ii) the level of eCBs is high in these slices and masks the 
potentiation. To address this concern, we performed several DSE protocols to determine 
if there is high eCB tone. Unfortunately, we did not observe DSE in any of the protocols.   
 
      Finally, we identified both chemical and electrical induction paradigms to induce LTD. 
DHPG-induced LTD is known to be dependent on endocannabinoids (Izumi and 
Zorumski, 2012). However, LFS-LTD may not require endocannabinoids as we did not 
observe any change in PPR. Future experiments will address the role of eCBs and BDNF 
in these paradigms to compare and contrast these forms of LTD. There are multiple forms 
of LTP and LTD, so experiments using different protocols and different experimental 
preparations may not share molecular mechanisms. Identifying which mechanisms are 
recruited under physiological conditions and disease conditions is critical. To this extent, 
the current work provides a repertoire of LTP and LTD paradigms to understand the role 
of BDNF and eCBs and their mechanism of action.  
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      Taken together, this chapter elucidates the interactions at cortical excitatory 
synapses. The first part addresses the effect of exogenous BDNF and BDNF-induced 
eCB release on excitatory neurotransmission. In the second part of the study, we explored 
different plasticity paradigms to study the functional relevance of these neuromodulator 
interactions.  
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Chapter 3 
Endogenous cannabinoids mediate effect of BDNF at CA1 inhibitory synapses in 
the hippocampus 
 
This chapter is a duplicate version of a manuscript currently under review: Selvam R, and 
Levine ES, Endogenous cannabinoids mediate effect of BDNF at CA1 inhibitory synapses 
in the hippocampus. 
 
R.S. and E.S.L. were responsible for conception and design of research; R.S. performed 
experiments and analyzed data. R.S. and E.S.L. interpreted the results of the 
experiments; R.S. prepared the figures and drafted the manuscript; R.S. and E.S.L, edited 
and revised the manuscript.  
 
3.1 Introduction 
     Brain derived neurotrophic factor (BDNF), a member of the neurotrophin gene family, 
plays a pivotal role in neuronal survival and differentiation, as well as the formation and 
maturation of synapses during development (Gottmann et al., 2009). BDNF binds to the 
tropomyosin receptor kinase B (TrkB) receptor as well as the pan-neurotrophin receptor 
p75. TrkB receptors are expressed throughout the central nervous system with the 
highest levels of expression in the neocortex and hippocampus (Masana et al., 1993). At 
the subcellular level, TrkB receptors are expressed in postsynaptic dendrites and axon 
terminals of GABAergic and glutamatergic neurons (Aoki et al., 2000; Cabelli et al., 1996; 
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Drake et al., 1999; Fryer et al., 1996; Gomes et al., 2006). In addition to its effects on 
survival and differentiation, BDNF modulates synaptic transmission at both inhibitory and 
excitatory synapses (Gottmann et al., 2009). Several studies have also shown the 
involvement of BDNF in long term potentiation (LTP), a cellular mechanism thought to be 
required for learning and memory (Lu et al., 2008; Minichiello, 2009). 
 
      BDNF modulates GABAergic neurotransmission, with acute effects that tend to be 
suppressive, but the mechanisms involved are unclear. In CA1 region of hippocampus, 
BDNF application reduced the amplitude of evoked inhibitory postsynaptic currents. A 
reduction in the paired-pulse ratio and a decrease in the coefficient of variation suggested 
a presynaptic site of action for this effect (Frerking et al., 1998). In rat hippocampal 
cultures, BDNF caused a rapid reduction in postsynaptic GABA receptor number that was 
responsible for a decrease in mIPSC amplitude (Brunig et al., 2001). A study by Mizoguchi 
et al. (Mizoguchi et al., 2006) suggested that the effect of BDNF on GABA release was 
dependent on age. BDNF suppressed mIPSC frequency and amplitude in hippocampal 
preparations of age P14 and P21 rats but not in P7 rats. A decrease in mIPSC frequency, 
mIPSC amplitude and decrease in release probability was also observed in visual cortex 
of BDNF heterozygous knockout mice suggesting that the BDNF may have both 
presynaptic and postsynaptic effects (Abidin et al., 2008; Abidin et al., 2006). In cerebellar 
granule cells, BDNF decreased both the amplitude and frequency of spontaneous and 
miniature postsynaptic currents also suggesting both pre- and postsynaptic effects 
(Cheng and Yeh, 2003). The effect of BDNF was blocked by inclusion of a TrkB antagonist 
in the postsynaptic cell in cerebellar granule cells (Cheng and Yeh, 2003). Taken 
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together, these results suggest that postsynaptic TrkB receptors are often required to 
initiate the effects of BDNF at GABAergic synapses, however the diversity of these effects 
indicates that the effects of BDNF at inhibitory synapses depend on several factors 
including age, brain area, and cell type.  
 
      In somatosensory cortex, we previously found that BDNF decreases the amplitude of 
spontaneous inhibitory postsynaptic currents, and this effect is initiated by postsynaptic 
TrkB activation but is expressed presynaptically. This effect was shown to be mediated 
by the postsynaptic release of endocannabinoids (eCBs) that act in a retrograde manner 
to suppress GABA release (Lemtiri-Chlieh and Levine, 2010). BDNF triggers the release 
of eCBs via phospholipase C pathway (Zhao and Levine, 2014; Zhao et al., 2015). In the 
hippocampus, BDNF has also been shown to acutely suppress presynaptic GABA 
release, however underlying mechanisms involved were not identified (Frerking et al., 
1998). In the present study, we focused on understanding the mechanism by which BDNF 
suppresses GABAergic neurotransmission in CA1 hippocampal pyramidal neurons. 
 
3.2 Materials and methods 
1. Slice preparation 
Briefly, Swiss CD1 mice (postnatal day 14–24) were anesthetized by 3.5% isoflurane 
inhalation, followed by decapitation. Whole brains were harvested quickly and immersed 
in ice-cold slicing solution containing (in mM) 110 choline chloride, 2.5 KCl, 1.25 
NaH2PO4-H2O, 25 NaHCO3, 0.5 CaCl2, 7 MgCl2-6H2O, 25 D-glucose, 11.6 sodium 
ascorbate, and 3.1 sodium pyruvate, equilibrated with 95% O2-5% CO2 (pH 7.4, 310±5 
                                                                                         
71 
 
mosmol/kg). Sagittal slices of 300 µm containing hippocampus were cut with a Dosaka 
EM DTK-1000 vibratome (Kyoto, Japan) and transferred to an incubating chamber. Slices 
were then incubated for 15 min at 34°C in incubating solution containing (in mM) 125 
NaCl, 2.5 KCl, 1.25 NaH2PO4- H2O, 25 NaHCO3, 0.5 CaCl2, 3.5 MgCl2-6H2O, 25 D-
glucose, 4 sodium lactate, 2 sodium pyruvate, and 0.4 ascorbic acid (pH 7.3, 310±5 
mosmol/kg) before being transferred to room temperature. Slices were then individually 
transferred to a recording chamber (room temperature) fixed to the stage of an Olympus 
BX51WI upright microscope fitted with a x40 water-immersion objective lens (0.8 NA). 
The recording chamber was continuously perfused at 2.0 ml/min with carboxygenated 
artificial cerebrospinal fluid (aCSF) consisting of (in mM) 125 NaCl, 2.5 KCl, 1.25 
NaH2PO4-H2O, 25 NaHCO3, 2 CaCl2.2H2O, 2 MgCl2-6H2O, and 25 D-glucose (pH 7.3, 
305±5 mosmol/kg). All animal procedures were conducted using protocols approved by 
the University of Connecticut Institutional Animal Care and Use Committee. 
 
2. Electrophysiology 
Whole cell recordings were obtained from hippocampal CA1 pyramidal neurons. Neurons 
were visually identified by their morphology and position under infrared differential 
interference contrast video microscopy. Patch electrodes (6–7 MΩ) were pulled from 
borosilicate glass capillaries using a Flaming/Brown P-97 micropipette puller (Sutter 
Instrument, Novato, CA). Pipette internal solution contained (in mM) 120 CsCl, 10.0 
HEPES, 10.0 phosphocreatine, 1.0 EGTA, 0.1 CaCl2, 4.0 Na2-ATP, 1.5 MgCl2, 0.4 Na-
GTP and 5.0 QX-314 (pH 7.4, 290±5 mosmol/kg). In all experiments, the chloride 
equilibrium potential (ECl) was close to 0 mV; thus spontaneous inhibitory postsynaptic 
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currents were recorded as inward currents at a holding potential of -70 mV. The ionotropic 
glutamate receptor antagonists 6,7-dinitroquinoxaline-2,3-dione (DNQX; 10 µM) and 3-
[(R)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP; 3 µM) were added to the 
bath solution to isolate inhibitory activity. To enhance spontaneous inhibitory activity, 
slices were treated with the muscarinic agonist carbachol (CCh; 10 µM). CCh, DNQX and 
CPP were present throughout all experiments and all drugs were delivered by bath 
perfusion, unless otherwise stated. Electrical currents were filtered at 2.9 kHz and 
digitized at >6 kHz using a HEKA EPC9 amplifier and ITC-16 digitizer (HEKA Elektronik, 
Darmstadt, Germany). Series resistance (Rs) was compensated up to 50% at 100 µs lag. 
Cells were rejected from analyses if input resistance (Ri) changed by >15% or fell below 
100 MΩ during the experiment. 
 
3. Analysis  
Off-line analysis was carried out using Clampfit 10.2 (Molecular Devices, Sunnyvale, CA) 
and Prism 7 (GraphPad Software, La Jolla, CA). Group data are reported as mean ± SE. 
Statistical comparisons were made using one-way ANOVA and Dunnett’s multiple 
comparison test or Student’s paired t-test for post hoc comparison.  
 
4. Chemicals 
Unless otherwise stated, drugs were obtained from Tocris Biosciences (Bristol, UK) and 
were delivered by bath perfusion or by intracellular application through patch pipette, as 
indicated. Stock solutions of BDNF (PeproTech, Rocky Hill, NJ), CPP (Sigma-Aldrich, 
St.Louis, MO) and carbachol were dissolved in 18 MΩ water. Stock solutions of WIN55-
                                                                                         
73 
 
212,2 (Cayman Chemicals, Ann Harbor, MI), DNQX (Sigma-Aldrich, St. Louis, MO), 
K252a, ANA-12, SR141716A, AM404, JZL184, URB597 and THL were dissolved in 100% 
dimethyl sulfoxide (DMSO). The final concentrations of the drugs were obtained by 
dilution in aCSF from stock solutions on the day of recording. The final concentration of 
DMSO did not exceed 0.1%, which by itself had no effect on synaptic transmission. 
 
3.3 Results 
3.3.1. BDNF depresses inhibitory transmission via postsynaptic TrkB receptors 
     The first set of experiments examined the effect of BDNF on pharmacologically-
isolated spontaneous inhibitory postsynaptic currents (sIPSCs) in CA1 pyramidal neurons 
in hippocampal slices. Under basal conditions, bath application of BDNF (0.8 nM) caused 
a significant decrease in the mean frequency (BL: 9.6 ± 0.9 Hz; BDNF: 8.1 ± 1.2 Hz; n=6, 
2 animals, p=0.0093) but no effect on mean amplitude (BL: 45.6 ± 7.7 pA; BDNF: 46.8 ± 
8.1 pA). Because spontaneous inhibitory activity was very low in the presence of 
glutamate receptor antagonists, the muscarinic agonist carbachol (CCh; 10 µM) was used 
to enhance action potential firing in interneurons (Kawaguchi, 1997; Lemtiri-Chlieh and 
Levine, 2007; Lemtiri-Chlieh and Levine, 2010; Trettel et al., 2004). In the presence of 
CCh, mean sIPSC amplitude increased to ~two-fold from 67.4 ± 9.1 pA to 132.2 ± 15.0 
pA (n=10, 2 animals, p=0.0035) and the frequency increased from 7.4 ± 0.6 Hz to 11.8 ± 
0.9 Hz (p=0.0001). As shown in the example sweeps in Fig. 3.1A, BDNF (0.8 nM) applied 
in the presence of carbachol caused a decrease in both mean sIPSC frequency (BL: 12.1 
± 1.2 Hz; BDNF: 10.6 ± 1.1 Hz; n=21, 8 animals) and amplitude (BL: 119.5 ± 8.2 pA; 
BDNF: 99.8 ± 7.9 pA). In order to capture changes in both the frequency and the 
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amplitude of action potential-dependent synaptic events, we integrated the area of 
individual IPSCs within specified bins to determine the total synaptic charge (Q; pA ms). 
As shown in Figure 1B, BDNF decreased mean sIPSC charge within 3-4 minutes of BDNF 
exposure. On average, the mean sIPSC charge decreased significantly to 79.4 ± 4.6% of 
CCh baseline (BL) after 8-10 mins of BDNF application (n=21, 8 animals, ANOVA 
F(20,240)=84.56, p<0.0001). Shown at the right are the data from individual cells comparing 
charge during a 3 min BL to min 8-10 of BDNF application (paired t-test, p=0.0002). 
Generally, sIPSC charge returned to baseline values ~ 10 minutes following BDNF wash 
out (105.5± 4.2 % of CCh BL; n=5, 1 animal). A similar effect was observed with BDNF 
at 2.0 nM concentration (Figure 3.1C; 3.1H). The mean sIPSC charge decreased 
significantly to 82.5 ± 3.9% of CCh BL (n=13, 3 animals, ANOVA F(12,144)=269.8, 
p=0.0006). Shown in the right panel are data from individual cells (paired t-test, 
p=0.0074).  
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Figure 3.1: BDNF depresses carbachol (CCh)-induced inhibitory synaptic currents in 
CA1 pyramidal neurons via activation of postsynaptic TrkB receptors. (A) 
Representative traces of spontaneous inhibitory postsynaptic currents (sIPSCs) during 
CCh baseline (BL) and in the presence of BDNF (0.8 nM). Scale bar: 200 pA, 5 s. (B) Left, 
Group data time course showing the effect of 0.8 nM BDNF on sIPSC charge (n=21; 8 
animals). Right, Data from individual cells during BL and minutes 8-10 of BDNF exposure. 
(C) Similar layout to (B), showing effect of 2.0 nM BDNF on sIPSC charge (n=13; 3 
animals). (D) Similar layout to (B), showing lack of effect of 0.8 nM BDNF in the presence 
of the TrkB receptor antagonist ANA-12 (10 µM; n=7; 2 animals). (E) Similar layout to (B), 
showing lack of effect of 0.8 nM BDNF with intracellular loading of the TrkB inhibitor K252a 
(200 nM; n=10; 2 animals). (F) Example traces for two separate exposures to BDNF in the 
same cell. Scale bar: 200 pA, 5 s. (G) Representative time course showing the effect of 
repeated exposure to BDNF (0.8 nM) on a single cell. (H) Group data showing the effect of 
BDNF on CCh-induced inhibitory activity under various conditions. *p<0.05. 
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     Next, we determined if the effect of BDNF on sIPSCs required TrkB receptor 
activation. As shown in the group time course and individual cells in Figure 3.1D and 
3.1H, application of BDNF had no significant effect on sIPSC charge in the presence of 
the competitive TrkB receptor antagonist ANA-12 (10 µM; 110.3 ± 15.6% of CCh BL; n=7, 
2 animals) suggesting that TrkB receptors are required to initiate the effect of BDNF. To 
address whether pre- or postsynaptic TrkB receptors are involved, we used the trk 
tyrosine kinase inhibitor K252a (200 nM) in the patch pipette to selectively block 
postsynaptic trk receptors (Madara and Levine, 2008). Intracellular application of K252a 
blocked the effects of BDNF on sIPSC charge as shown in Figure 3.1E and 3.1H (113.9 
± 15.5% of CCh BL; n=10, 2 animals). These results suggest that postsynaptic TrkB 
receptor activation is required for the effect of BDNF on CCh-induced inhibitory synaptic 
activity. 
 
     As evident from the data from individual experiments, the magnitude of the BDNF 
effect is highly variable across cells. We therefore examined whether the effect of 
repeated application of BDNF is consistent within a particular cell, which is important 
when employing manipulations predicted to alter the magnitude of the BDNF effect. For 
these experiments, BDNF was applied for two 5-minute exposures separated by 20 min. 
In each instance, the magnitude of the BDNF effect was normalized to the CCh BL prior 
to each application. Example traces and an individual time course for repeated BDNF 
exposure on the same cell is shown in Figure 3.1F and G. As can be seen in this example, 
and in the group data in Figure 3.1H, the effect of five-minute exposure to BDNF is 
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reversible and the magnitude of the effect is similar across trials (BDNF 1: 79.3 ± 3.3% of 
CCh BL; BDNF 2: 81.2 ± 3.7 % of CCh BL; n=9, 2 animals). 
 
3.3.2. Effect of BDNF requires activation of CB1 cannabinoid receptors: 
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Figure 3.2: BDNF suppression of inhibitory transmission requires activation of type I 
cannabinoid (CB1) receptors. (A) Representative traces during BL and in the presence of 
CB1 receptor agonist WIN (5 µM). Scale bar: 200 pA, 2 s. (B) Group data time course showing 
the suppressive effect of WIN on sIPSC charge (n=9; 2 animals). (C) Representative traces of 
sIPSCs in the presence of the CB1 receptor antagonist SR141716A (SR; 10 µM) alone and in 
the presence of SR and BDNF. Scale bar: 200 pA, 2 s. (D) Group data time course showing 
lack of effect of 0.8 nM BDNF in the presence of SR (n=18; 5 animals). (E) Group data showing 
the effect of WIN and BDNF on CCh-induced inhibitory activity under various conditions. Also 
shown for comparison are the BDNF group data from Figure 1G (red). (F) Data from an 
individual cell showing the effect of 0.8 nM BDNF on sIPSC charge in the first trial and the lack 
of effect of BDNF in the presence of SR in the second trial. (n=8; 2 animals).  Each data point 
is individual cells by color. *p<0.05. 
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     Based on our previous results in somatosensory cortex (Lemtiri-Chlieh and Levine, 
2010), we hypothesized that the effect of BDNF could be mediated by eCB release from 
postsynaptic CA1 neurons in hippocampus. We first examined whether the effect of 
BDNF was mimicked by application of a CB1 receptor agonist. As shown in example 
traces and group time course in Figure 3.2A and 3.2B, acute application of the 
cannabinoid agonist WIN55,212-2 (5 µM) caused a reduction of sIPSC charge to 70.4 ± 
8.0% of CCh BL. This effect lasted for the duration of WIN exposure and did not recover 
to baseline values during the experiment (n=9; 2 animals, paired t-test, p=0.0108). This 
suppressive effect of WIN is similar to the effect of BDNF (Figure 3.2E). Next, we tested 
the effects of BDNF in the presence of the CB1 receptor antagonist SR141716A (SR; 10 
µM). A representative trace of effect of BDNF in the presence of SR is shown in Figure 
3.2C. The group time course shown in Figure 3.2D and 3.2E illustrates that BDNF failed 
to suppress inhibitory activity in the presence of SR (101.2 ± 5.7% of BL; n=18; 8 animals).  
 
 
     Next, we tested the effects of SR in the presence of BDNF using the within-cell 
experimental design. For the second application, BDNF was applied in the presence of 
SR. Consistent with the results obtained above, BDNF decreases sIPSC charge to 68.2 
± 4.8% of BL in 1st trial and SR prevented the suppressive effects of BDNF to 92.1 ± 3.3% 
of BL in 2nd trial as shown in Figure 3.2F (n=8; 2 animals, paired t-test, p=0.02). All cells 
showed a decreased effect of BDNF in the presence of SR. Together, these results 
suggest that CB1 receptors are required for the suppressive effects of BDNF on 
carbachol-induced inhibitory activity. 
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3.3.3 Effect of BDNF is mediated by postsynaptic endocannabinoid release: 
      Because the effect of BDNF requires activation of postsynaptic TrkB receptors, we 
hypothesized that endocannabinoids are released from postsynaptic CA1 neurons. It has 
previously been established that intracellular loading of the membrane-impermeable eCB 
transport inhibitor 
AM404 can be used to 
block eCB release 
(Lemtiri-Chlieh and 
Levine, 2010; Maglio et 
al., 2018; Ronesi et al., 
2004; Yeh et al., 2017; 
Zhao et al., 2015). As 
shown in the 
representative traces in 
Fig. 3.3A, we found that 
including AM404 (5 
µM) in the patch pipette 
disrupted the effect of 
BDNF. The group time course is shown in Figure 3.3B (109.2 ± 9.2% of CCh BL; n=8; 1 
animal). These results suggest that endocannabinoids are released from the postsynaptic 
cell. 
  
 
Figure 3.3: Effect of BDNF is mediated by endocannabinoids. 
(A) Example traces during BL and BDNF in the presence of 
intracellular transport inhibitor AM404 (5 µM). Scale bar: 200 pA, 
2 s. (B) Group time course showing lack of effect of 0.8 nM BDNF 
with intracellular loading of AM404 (5 µM; n=8; 1 animal). (C) 
Example traces of BDNF on first exposure and BDNF in the 
presence of reuptake inhibitor AM404 (25 µM) on second 
exposure on the same cell. Scale bar: 200 pA, 5 s. (D) Group data 
showing the effect of 0.8 nM BDNF alone and in the presence of 
AM404 on sIPSC charge (25 µM; n=19; 5 animals). *p<0.05.  
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     AM404 can also be used extracellularly to block reuptake of eCBs, and bath 
application of AM404 in vitro has been shown to enhance the magnitude of eCB-mediated 
plasticity, including depolarization-induced suppression of inhibition (DSI) and long term 
depression (LTD) (Beltramo et al., 1997; Du et al., 2013; Fortin et al., 2004; Sheinin et 
al., 2008; Trettel et al., 2004; Wilson and Nicoll, 2001). Because of the variability in the 
magnitude of the BDNF effect across cells, we examined the effect of bath-applied AM404 
using the within-cell experimental design. Representative traces from a single experiment 
are shown in Figure 3.3C, showing a greatly enhanced effect of BDNF in the presence of 
AM404, while AM404 itself did not affect baseline activity. Data for each experiment is 
shown in Figure 3.3D. BDNF in the presence of AM404 significantly depressed sIPSC 
charge to 73.1 ± 4.9% of BL in 2nd trial compare to BDNF alone (98.5 ± 5.8% of BL; n=19; 
5 animals, paired t-test, p=0.0003).) In this cohort of cells, there were several cells that 
did not show a decrease to the first BDNF application, however most of those cells did 
show a decrease to BDNF in the presence of AM404. These results suggest that BDNF 
triggers the release of eCBs that in turn mediate the effect on CCh-induced inhibitory 
activity.  
 
3.3.4. Effect of BDNF is mediated by 2-AG: 
      We have previously shown that, at inhibitory synapses of somatosensory cortex, 
BDNF causes release of 2-AG that acts retrogradely on presynaptic terminals to suppress 
GABA release (Lemtiri-Chlieh and Levine, 2010). We therefore investigated whether the 
eCB released by BDNF at hippocampal inhibitory synapses is also 2-AG. To address this, 
we blocked the synthesis of 2–AG using the diacylglycerol (DAG) lipase inhibitor 
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tetrahydrolipostatin (THL; 25 µM). As shown in the sample traces (Figure 3.4A) and group 
time course, bath application of THL completely prevented the effects of BDNF (Figure 
3.4B; 103 ± 5% of BL; n=13; 2 animals). We further explored the involvement of 2-AG 
using the monoacylglycerol lipase (MAGL) inhibitor JZL184 to increase 2-AG levels by 
preventing breakdown (Kiritoshi et al., 2016; Pan et al., 2009; Schlosburg et al., 2010; 
Wang et al., 2016). As shown in Fig. 3.4C and 3.4D, BDNF in the presence of JZL184 
depressed sIPSC charge to 69.3 ± 4.4% of BL, a significantly enhanced effect compared 
to BDNF alone (91.8 ± 3.6% of BL) (n=18; 5 animals, paired t-test, p=0.0125). These 
results suggest the BDNF causes release of 2-AG to suppress spontaneous inhibitory 
activity. 
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      The potential role 
of BDNF-induced 
anandamide release 
was explored by 
blocking anandamide 
degradation with the 
fatty acid amide 
hydrolase (FAAH) 
inhibitor URB597 (2 
µM). Example traces 
of BDNF and BDNF 
in the presence of 
URB597 are shown 
in Figure 3.4E. BDNF 
caused reduction in 
charge to 88.2 ± 
2.7% of BL in 1st trial 
and in the presence 
of URB597, BDNF 
similarly decreased 
the charge to 91.0 ± 2.9% of BL in 2nd trial as shown in Figure 3.4F (n=17; 3 animals). 
These results suggest that blocking anandamide degradation does not alter the effects of 
BDNF.  
  
Figure 3.4: BDNF causes the release of 2-arachidonoylglycerol (2-
AG).  (A) Representative traces during baseline and BDNF exposure 
in the presence of the DAG lipase inhibitor, Tetrahydrolipostatin (THL; 
5 µM). Scale bar: 200 pA, 2 s. (B) Group data time course showing 
lack of effect of 0.8 nM BDNF with THL (5 µM; n=13; 2 animals). (C) 
Representative traces of BDNF on first exposure and BDNF in the 
presence of monoacylglycerol lipase (MAGL) inhibitor JZL184 (500 
nM) on the same cell. Scale bar: 200 pA, 5 s (D) Data from individual 
cells showing the effect of 0.8 nM BDNF alone and in the presence of 
JZL184 (500 nM; n=18; 5 animals). (E) Similar to (C), showing the 
BDNF on first exposure and in the presence of fatty acid amide 
hydrolase (FAAH; 2 µM) inhibitor. Scale bar: 200 pA, 5 s (F) Similar to 
(D), showing the effect of 0.8 nM BDNF alone and in the presence of 
URB597 on sIPSC charge (2 µM; n=17; 3 animals). * p<0.05.  
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3.4. Discussion 
      BDNF and eCBs are potent neuromodulators that are highly expressed throughout 
the forebrain, including the hippocampus, and play critical roles in many behavioral and 
physiological processes. Interestingly, disruption of either BDNF or eCB signaling is 
associated with an overlapping set of neurologic and psychiatric diseases, including 
anxiety, depression, seizure disorders, and schizophrenia (Hill and Patel, 2013; Lupica et 
al., 2017; McNamara and Scharfman, 2012). As a result, these systems are of high 
interest for the development of novel therapeutics (Autry and Monteggia, 2012; Patel et 
al., 2017).  
 
    The present results indicate that the BDNF-induced suppression of inhibitory 
transmission at CA1 pyramidal cell synapses results from activation of postsynaptic TrkB 
receptors, which causes mobilization of 2-AG that acts retrogradely on presynaptic CB1 
receptors. On average, BDNF (0.8 nM) caused a ~25% decrease in CCh-induced 
inhibitory activity. This is consistent with the results obtained in other studies on the effect 
of BDNF on GABAergic transmission (Frerking et al., 1998; Tanaka et al., 1997). The 
effect of BDNF was triggered by postsynaptic activation of TrkB receptors as loading the 
postsynaptic neuron with the trk tyrosine kinase inhibitor K252a was sufficient to prevent 
the BDNF effect. We should also note that K252a is membrane permeable drug and 
therefore could diffuse outside the cell to block presynaptic TrkB receptors. Previous work 
in our lab, however, found that intracellular K252a prevented the postsynaptic effect of 
BDNF at glutamatergic synapses but did not block the presynaptic effect on mEPSC 
frequency (Madara and Levine, 2008). The effect of BDNF in the present studies was 
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also blocked by a CB1 receptor antagonist and mimicked by a CB1 receptor agonist, 
suggesting that activation of CB1 receptors is required for BDNF suppression of 
GABAergic transmission. Further, we found that the effect of BDNF was disrupted by 
blocking 2-AG synthesis and enhanced by blocking 2-AG degradation. 
 
      Presynaptic effects of BDNF at inhibitory synapses have been identified in multiple 
brain regions. In an earlier study of CA1 pyramidal neurons in hippocampus, BDNF 
caused a decrease in the evoked inhibitory response and an increase in the paired-pulse 
ratio suggesting a presynaptic mechanism (Frerking et al., 1998). Chronic application of 
BDNF on solitary neurons cultured from rat visual cortex caused a reduction in mIPSC 
frequency but not in mIPSC amplitude also suggesting a presynaptic effect (Palizvan et 
al., 2004). We have previously shown that the effect of BDNF at layer 2/3 inhibitory 
synapses of somatosensory cortex is expressed presynaptically using three different 
approaches: an increase in the paired pulse ratio (PPR), an increase in mIPSC frequency 
with no change in mIPSC amplitude, and a decrease in the coefficient of variation (Lemtiri-
Chlieh and Levine, 2010). Further, several studies have presented evidence of synaptic 
localization of CB1 and TrkB receptors – both are highly expressed in cortex and 
hippocampus (Cabelli et al., 1996; Egertova et al., 2003; Fryer et al., 1996; Marsicano 
and Lutz, 1999; Matsuda et al., 1993; Miller and Pitts, 2000; Tsou et al., 1998). The 
present study provides evidence that the effects of BDNF at CA1 synapses are mediated 
by eCBs, which may generalize to inhibitory synapses throughout the nervous system. 
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     BDNF-induced mobilization of eCBs most likely involves 2-AG, as blocking DAG lipase 
to prevent 2-AG synthesis disrupted the effect of BDNF, and blocking MAG lipase to 
increase 2-AG levels enhanced the effect of BDNF. Although the specific signaling 
mechanisms for BDNF-induced 2-AG release have not been identified, it is likely that 
postsynaptic PLCƔ signaling is involved. TrkB receptor activation and subsequent PLCƔ 
signaling can generate diacylglycerol (DAG) which can then be converted to 2-AG by 
DAG lipase. This signaling pathway is similar to 2-AG mobilization in response to 
metabotropic glutamate receptor (mGluR) or muscarinic receptor activation. Our previous 
work at layer 2/3 inhibitory synapses in somatosensory cortex supports the conclusion 
that BDNF-induced eCB release requires PLCƔ signaling and is independent of mGluR 
activation (Zhao and Levine, 2014). Similarly, in cerebellar Purkinje cells, BDNF 
modulates GABA receptor function via TrkB receptor-PLCƔ signaling cascade (Cheng 
and Yeh, 2005). Further, elevated calcium is not necessary for mGluR-induced 
(Hashimotodani et al., 2005; Maejima et al., 2005; Ohno-Shosaku et al., 2005) or CCh- 
induced eCB release (Kano et al., 2009). However, BDNF requires elevated calcium 
through calcium intracellular stores or calcium influx to mediate its effects (Amaral and 
Pozzo-Miller, 2012). It has been shown at inhibitory synapses of somatosensory cortex, 
intracellular calcium is required for BDNF to trigger the release of eCBs (Lemtiri-Chlieh 
and Levine, 2010). It is thus possible that different signaling mechanisms could be 
involved in mGluR-induced, CCh-induced and BDNF-induced 2-AG release. 
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      There is a growing body of evidence supporting interactions between BDNF and eCB 
signaling. In the current study, we have shown that BDNF induces eCB release to 
suppress GABAergic neurotransmission in the hippocampus, similar to previous results 
in somatosensory cortex. We have also shown that endogenous BDNF, released in 
response to theta-burst stimulation, triggers the release of eCBs that mediate inhibitory 
long-term depression (iLTD) at layer 2/3 inhibitory synapses of somatosensory cortex 
(Zhao et al., 2015). In addition, BDNF induces eCB release at layer 5 excitatory synapses 
of somatosensory cortex, where eCB signaling acts to limit the direct potentiation of 
glutamate release triggered by BDNF (Yeh et al., 2017). BDNF also appears to increase 
eCB production in ventral tegmental area dopamine neurons to facilitate DSI and 
inhibitory LTD (Zhong et al., 2015). BDNF can inhibit CB1 receptor function in striatum 
and this effect is mediated by cholesterol metabolism (De Chiara et al., 2010). On the 
other hand, BDNF has been shown to mediate CB1 receptor-dependent protection 
against excitotoxicity (Khaspekov et al., 2004; Marsicano et al., 2003). CB1 receptor 
signaling results in striatal neuroprotection from excitotoxicity via the phosphatidylinositol 
3-kinase/Akt/mammalian target of rapamycin complex 1 pathway, which, in turn, induces 
BDNF expression through BDNF gene promoter IV (Blazquez et al., 2015). In visual 
cortex, BDNF opposes eCB-mediated heterosynaptic LTD by inducing homosynaptic 
long term potentiation (Huang et al., 2008). In addition, eCBs released by action potential 
bursts of layer 5 pyramidal neurons of barrel cortex are crucial for the induction of BDNF-
mediated LTP at excitatory synapses (Maglio et al., 2018). Understanding the 
mechanistic basis of these varied interactions will provide insights into the physiological 
roles of BDNF and eCBs in regulating synaptic transmission. 
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Chapter 4 
Discussion and Conclusions 
 
4.1 Summary and interpretation of findings  
               The studies conducted 
in this dissertation 
explored interactions 
between BDNF and 
endocannabinoids in the 
context of cortical 
excitatory synaptic 
transmission and 
hippocampal inhibitory 
synaptic transmission. In 
Chapter 2, the first set of 
experiments examined 
the interactions between 
BDNF and eCBs at 
cortical excitatory 
synapses. We chose layer 5 excitatory synapses as we have shown that these synapses 
receive cannabinoid-sensitive inputs, whereas inhibitory synapses in this layer are 
relatively cannabinoid-insensitive (Fortin and Levine, 2007).  We found that BDNF by itself 
did not alter excitatory neurotransmission.  However, in the presence of a CB1R 
  
Figure 4.1 Simplified scheme summarizing the 
interactions between BDNF and eCBs at cortical 
excitatory synapses.  BDNF modulates presynaptic 
release probability at cortical glutamatergic synapses via 
competing effects. BDNF activates presynaptic TrkB 
receptors to directly enhance release probability, while 
simultaneously triggering the postsynaptic release of 
endocannabinoids that act to decrease release via 
presynaptic CB1 receptors. 
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antagonist, BDNF produced an increase in excitatory neurotransmission. Similarly, 
blocking the release of eCBs also unmasked the effect of BDNF. Thus, we were able to 
detect the effect of BDNF by blocking eCB release or CB1Rs. Consistent with our 
previous results in layer 2/3 somatosensory cortex, BDNF triggers the release of eCBs 
from postsynaptic cells to act on presynaptic CB1 receptors. This effect opposes the 
direct presynaptic facilitatory effect of BDNF on glutamate release. Thus, the net effect 
on glutamate release we observe at these synapses depends on the influence of BDNF 
and eCBs. These findings are summarized in figure 4.1. 
 
     In the latter part of Chapter 2, we focused on examining the functional relevance of 
BDNF and eCBs in the context of long term synaptic plasticity – potentiation and 
depression (LTP/LTD).  Using a chemical induction protocol of forskolin and rolipram, we 
identified a form of LTP in layer 5 excitatory synapses. This form of LTP does not require 
BDNF signaling.  In addition, blocking CB1Rs did not alter the LTP indicating that eCBs 
are also not involved in this form of chemical LTP.  We also used several electrical 
stimulation protocols to induce LTP, nevertheless, we do not have a paradigm to study 
LTP at layer 5 excitatory synapses.  We have identified several forms of LTD- mGluR 
dependent LTD and low frequency stimulation (LFS) to study the role of BDNF and eCBs 
in these paradigms at layer 5 excitatory synapses.  
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     The second data chapter (chapter 3) of the thesis focused on examining whether 
BDNF induces the release of eCBs at CA1 inhibitory synapses of hippocampus.  
Consistent with our 
previous results in the 
neocortex, we found 
that the acute 
application of BDNF 
caused a reduction in 
GABAergic 
transmission onto 
pyramidal neurons in 
CA1 hippocampus.  
This effect requires 
postsynaptic activation 
of TrkB receptors and 
presynaptic CB1 
receptors.  By blocking eCB release, we disrupted the effect of BDNF on spontaneous 
inhibitory activity.  By blocking the reuptake of eCBs, we enhanced the effect of BDNF on 
spontaneous inhibitory activity.  These results indicate that BDNF indeed triggers the 
release of eCBs from the postsynaptic cell and subsequent activation of presynaptic 
CB1Rs.  We also implicated the specific ligand released by BDNF as 2-AG since blocking 
the synthesis of 2-AG disrupted the effect of BDNF while blocking the degradative 
enzyme of 2-AG enhanced the effect of BDNF.  Similar to somatosensory cortex, we 
  
Figure 4.2 Schematic summarizing the findings of 
hippocampal excitatory synapses. BDNF suppress 
inhibitory activity at GABAergic synapses at CA1 
hippocampus. BDNF activates postsynaptic TrkB receptors 
and triggers the release of 2-arachidonoyglycerol (2-AG) that 
acts on presynaptic CB1 receptors to suppress GABA 
release.  
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identified a BDNF/TrkB signaling that can induce eCB release to act retrogradely to inhibit 
GABA release at CA1 inhibitory synapses of hippocampus. These results are 
summarized in figure 4.2. 
 
4.2. Functional impact of BDNF-eCB interactions on cortical and hippocampal 
synaptic plasticity 
    The major cortices identified in mammals include sensory cortex, motor cortex and 
association cortices (like prefrontal cortex).  Within sensory cortices, we have visual, 
auditory and somatosensory cortex. These cortices are processed by assemblies of 
neurons arranged into 6-layer cortical columns.  Layer 5 is the main output layer of cortical 
processing. Layer 5 also receives inputs from thalamus in addition to cortex. Layer 2/3 
pyramidal neurons have principally intracortical connections. Inhibitory interneurons are 
also crucial for information processing and signal integration.  Understanding the local 
inhibitory and excitatory microcircuits is essential to understand how information is 
processed in a given cortical circuit (Méndez and Bacci, 2011).   
 
      Somatosensory cortex is a good model system because of its accessibility in the 
rodent brain and also because of the somatotopic representation of whiskers. Receptive 
field mapping studies have enabled us to identify the somatosensory topographic maps 
in this region.  The somatosensory cortex is well defined and studied in terms of circuitry 
and function, laminar specificity, neural network and plasticity, sensorimotor integration, 
coding and tactile perception. The “critical period” (defined as the time period during which 
the presence of certain factors are crucial for the development) concept was first identified 
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in somatosensory cortex using whisker-barrel development from the ocular dominance 
plasticity studies.  Cortical circuits are refined by sensory experience during critical 
periods of development as well as in adulthood. eCBs and BDNF have been found to be 
involved in experience-dependent refinement of cortical circuits (Huang et al., 2008; Jiang 
et al., 2010). For instance, GABAergic circuits are regulated by sensory experience via 
release of endogenous BDNF. Knocking out BDNF reduced GABA release from fast 
spiking interneurons and decreased perisomatic inhibition. Thus, activity dependent 
secretion of eCB and BDNF makes them suitable models to study the shaping of cortical 
microcircuits (Jiao et al., 2011). 
 
     Endocannabinoid-dependent forms of plasticity are good models to study local 
modulation of somatosensory cortex. CB1R is highly expressed in layer 2/3 and 5 of 
cortex. In layer 2/3, both inhibitory and excitatory inputs are sensitive to 
endocannabinoids. However, in layer 5 only excitatory inputs are sensitive to 
endocannabinoids and hence we used layer 5 as our model system to study synaptic 
plasticity.  CB1Rs are predominantly expressed on presynaptic basket cells and 
calbindin-positive cells.  By selectively suppressing perisomatic inhibitory transmission 
and increasing pyramidal neuron excitability, eCB signaling may enhance the output from 
layer 2/3 to layer 5.  eCB signaling in layer 2/3 of the cortex mediates STDP by enhancing 
dendritic backpropagation.  For instance, layer 5 PNs, pre and post-pairing produced LTP 
at proximal synapses while producing LTD at distal synapses. With boosting of dendritic 
backpropagation, LTD at distal inputs switched to LTP in response to the same induction 
protocols.  The eCBs are involved in modulation of dendritic backpropagation which may 
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have consequences for regulating the magnitude and direction of STDP (Hsieh and 
Levine, 2013). Collectively, eCB signaling in different cortical layers exhibits diverse 
effects and each could have an impact on different aspects of cortical information 
processing.  
 
      Other sensory cortex like motor cortex or visual cortex also share same laminar 
patterns of CB1R distribution and we can hypothesize that layer 2/3 of the cortical layers 
may all behave the same in sensory cortices – BDNF modulating the release of eCBs to 
suppress GABA release. There might be differences across cortical layers (comparison 
of layer 2/3 to layer 5) in each of these sensory cortices. In general, in all these cortices, 
CB1R is more prominently observed in GABAergic terminals. Hence, we can extend our 
findings in somatosensory cortex to other layers/areas of cortex and how they are 
functionally relevant in the context of synaptic plasticity.  
 
     On the other hand, prefrontal cortex, an association cortex is involved in higher 
cognitive and executive functions like mood, working memory, planning and attention. 
TrkB receptors are highly expressed in cortical layers II-VI in prefrontal cortex. CB1Rs 
are also highly expressed in all layers of prefrontal cortex but predominantly localized in 
GABAergic interneurons.  There is a striking similarity in the distribution pattern of CB1 
and TrkB receptors in prefrontal cortex and somatosensory cortex.  This makes it possible 
to address the questions that have be addressed in somatosensory cortex to this region.  
What layer of prefrontal cortex acts similar to layer 2/3 inhibitory synapses and layer 5 
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excitatory synapses of somatosensory cortex? Further, the discovery of a single 
nucleotide polymorphism (SNP) resulting in a Val to Met switch at codon 66 of the gene 
encoding for BDNF has facilitated the study of BDNF role in synaptic plasticity and 
cognitive function in motor cortex and hippocampus, but has not been addressed in 
prefrontal cortex.  Cortical circuits are refined by sensory experience in somatosensory 
cortex.  Similarly, in prefrontal cortex, the circuity are refined by sensory experience, 
insult/injury, paternal affection – yet another question that we can explore is how does 
cortical circuits are shaped in prefrontal cortex. CB1R interacts with the dopaminergic 
system in medial prefrontal cortex to regulate GABA mediated inhibition of pyramidal 
output neurons as described in the (Chiu et al., 2010) study.  These evidences suggest 
that eCBs might interact with dopaminergic system/reward pathways in prefrontal cortex 
as they are involved in higher order cognitive functions.  The few questions that can be 
addressed in the context of synaptic plasticity are: Is there any interaction between BDNF 
and eCBs in this region? What is their functional relevance?  
 
   The hippocampus is important for both spatial and non-spatial forms of declarative or 
explicit memory.  Information flows through the cortico-hippocampal circuit.  In the 
classical pathway, CA1 is the major output pathway of hippocampus.  Most of the 
excitatory input comes from entorhinal cortex.  The information is transmitted through the 
trisynaptic path. CA1 has local GABAergic interneurons; these target CA1 pyramidal 
neuron somas or axons to modulate pyramidal neuron activity in a domain specific 
manner.  CB1R is highly expressed in hippocampal layers including CA1, CA3 and 
dentate gyrus.  Our results in CA1 inhibitory synapses of hippocampus are very similar to 
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the results we obtained in layer 2/3 inhibitory synapses of somatosensory cortex.  In both 
cases, BDNF causes the release of eCBs to modulate GABAergic neurotransmission.  
We can extend these studies to excitatory synapses of CA1 or CA3 to identify if the effects 
of BDNF are similar to layer 5 excitatory synapses of somatosensory cortex (Basu and 
Siegelbaum, 2015; Basu et al., 2013).   Understanding how each hippocampal layer 
functions and its relevance in synaptic plasticity is crucial to understanding how 
information is processed in different hippocampal circuits. Similar to somatosensory 
cortex, endocannabinoid-mediated plasticity is very well studied in hippocampus. DSI was 
first observed in hippocampus. Tetanus stimulation causes a long lasting suppression of 
inhibition termed as LTD and eCBs are potent mediators of LTD in this region (reviewed 
in (Castillo et al., 2012; Heifets and Castillo, 2009)). BDNF also mediates several forms 
of LTP in hippocampus (reviewed in (Edelmann et al., 2014)). Endogenous BDNF is 
required for the presynaptic component of LTP but not for the postsynaptic component at 
CA1-CA3 synapses. Further, BDNF release in hippocampus is also experience 
dependent. Short-term depression does not require BDNF but long-term depression 
requires BDNF (Aarse et al., 2016).  
 
    To sum up, activity-dependent secretion of BDNF and eCBs makes them a viable 
model to study the activity-dependent cortical information flow or to study the 
corticohippocampal circuit. In summary, studying the input-specific and region-specific 
effects of eCB and BDNF signaling as well as their interactions will provide insights in 
understanding the regulation of corticohippocampal or cortical circuits and the same 
questions can be addressed in other cortical areas as well.  
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4.3 BDNF and eCB signaling at cortical excitatory synapses  
     We focused on somatosensory cortex, where CB1 and TrkB receptors are highly 
expressed in layers 2/3 and 5. Further, in layer 2/3, depolarization-induced eCB release 
targets both inhibitory and excitatory neurotransmission. The net effect is an increase in 
pyramidal neuron excitability due to disinhibition. However, in layer 5, depolarization-
induced eCB release results in DSE at excitatory synapses and the majority of inhibitory 
inputs are cannabinoid-insensitive. Thus, the net effect of a brief depolarization in layer 
5 is a decrease in pyramidal neuronal excitability (Fortin et al., 2004). In contrast, we and 
others have shown that BDNF can modulate excitatory neurotransmission 
presynaptically (Crozier et al., 1999; Levine et al., 1998; Levine et al., 1995). Thus, layer 
5 is an ideal place to address interactions at excitatory synapses. We used this as our 
model system to address the question whether BDNF induces eCB release.  
 
      One of the future questions that needs to be addressed is how BDNF and eCBs 
interact to modulate action potential-dependent glutamate release. We have shown that 
at inhibitory synapses in layer 2/3 of somatosensory cortex, BDNF causes a reduction in 
evoked IPSCs by triggering eCB release (Lemtiri-Chlieh and Levine, 2010). However, 
there is clearly lack of evidence for the effects of BDNF on evoked glutamate release. In 
addition, evoked and spontaneous glutamate release derive from distinct vesicle 
populations and use distinct mechanisms (Atasoy et al., 2008; Melom et al., 2013; Peled 
et al., 2014; Walter et al., 2014).  Hence, it is critical to identify if BDNF and eCBs interact 
differently with regard to evoked glutamate release.  
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      Similar to the effect of exogenous BDNF on glutamate release, we determined the 
role of endogenous BDNF in mediating synaptic plasticity, LTP. The chemical induction 
protocols did not require BDNF or eCB signaling. It is possible that the net effect of BDNF 
on LTP is so negligible that we do not see it.  The chemical induction protocol regulates 
cAMP levels to activate downstream signaling pathways to potentiate at these synapses 
(Otmakhov et al., 2004). However, we know that eCBs can inhibit adenylyl cyclase 
thereby reducing cAMP levels (Castillo et al., 2012; Chevaleyre et al., 2007). On the 
other hand, BDNF can increase cAMP levels to facilitate LTP (Lu et al., 2008). There are 
three key players in regulating cAMP levels in this form of plasticity (cyclic AMP synthesis 
and breakdown, BDNF and eCBs) and this complexity meant that it was not possible to 
determine the effect.  Another factor to add to this equation is the direct presynaptic 
effects of BDNF against BDNF triggered eCB release at postsynaptic sites. Depending 
on the net effect of glutamate release, the direction of plasticity will change. The outcome 
of this interaction might vary and be complicated, yet, it will be interesting to examine the 
roles of each component in this plasticity.  One possibility is that subthreshold 
concentrations of BDNF in combination with shorter duration of forskolin induction will 
reveal a role for BDNF.  
 
     Assuming the eCBs are potently inhibiting glutamate release, blocking CB1 receptors 
will unmask the effects of BDNF. Adding TrkB receptor antagonists to the existing 
equation will help us in determining the role of BDNF in LTP.  Another possibility that we 
will consider is BDNF might activate TrkB receptors which in turn will activate MAPK 
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signaling pathway to induce LTP (Patterson et al., 2001). This type of BDNF-induced 
LTP will be an eCB-independent form of LTP.  
 
      Electrical stimulation protocols at layer 5 excitatory synapses, including HFS, TBS, 
and pairing protocols, did not elicit LTP in our studies. This could be due to several 
possibilities: (a) inability to recapitulate the microcircuit and (b) the stimulation patterns 
are not sufficient to induce LTP. To rule this out, we will repeat the stimulation patterns 
in CA1 or CA3 hippocampus to elucidate LTP.  If we obtain LTP in hippocampus, it 
suggests that there is region-specificity and layer-specificity to LTP in cortex. 
Alternatively, if the inhibition of excitatory inputs is high then we will not be able to induce 
LTP as the endogenous eCBs levels are high and the net effect on glutamate release 
favors the eCB influence. If this is true, we should be able to obtain DSE at these 
synapses. However, with stimulation protocols we used at these synapses, we failed to 
induce DSE indicating that the eCBs levels are not sufficient to block LTP.  
 
      Similarly, we used different LTD-inducing paradigms to test the involvement of BDNF 
and eCBs. Bath application of DHPG induces mGluR-dependent LTD which also 
requires eCB signaling. We will test the involvement of BDNF in this form of LTD. Low 
frequency stimulation induces eCB-independent LTD. Having eCB- 
dependent/independent and BDNF- dependent/independent forms of plasticity will help 
uncover the mechanisms involved in each form of LTD/LTP. We can compare and 
contrast these forms of plasticity as these interactions might have significant roles in 
shaping synaptic plasticity thereby contributing to the brain circuits’ activity.  
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4.4 Future directions for studying BDNF-eCB interactions at cortical excitatory 
synapses 
     Over the past decade, there has been growing evidence for BDNF-eCB interactions, 
yet the mechanisms involved are largely unknown. The studies presented in this 
dissertation characterized the effects of BDNF and eCBs at layer 5 cortical excitatory 
synapses as well as CA1 hippocampal inhibitory synapses. Many questions still remain 
to be answered. For instance, an immediate question is to determine whether BDNF and 
eCBs interact to modulate glutamate release in response to stimulation (high frequency, 
low frequency or theta burst stimulation paradigms). Next, we would like to determine 
the role of endogenous BDNF in excitatory neurotransmission. Although we have some 
preliminary evidence suggesting that BDNF and eCBs are not involved in a chemically-
induced form of LTP, we would like to refine the answers to these questions. An 
immediate question we will address is whether there is an enhancement of forskolin-
induced potentiation at three time points (5 minutes, 10 minutes and 15 minutes of 
treatment) at layer 5 excitatory synapses.  We will use subthreshold concentrations of 
BDNF in combination with forskolin induction to induce LTP. If the LTP is dependent on 
BDNF, we will identify the downstream signaling pathway from BDNF that causes LTP 
induction. 
 
     Similar to the effect of exogenous BDNF we observed at inhibitory synapses of cortex 
and hippocampus, we will extend the current findings to CA1 excitatory synapses of 
hippocampus as well.  An immediate question we will address at CA1 excitatory 
synapses is whether BDNF triggers the release of eCBs as we have already shown that 
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BDNF can induce eCB release at layer 5 excitatory synapses. Next, we will perform a 
set of experiments with chemical induction paradigms to elucidate LTP and to determine 
the role of BDNF in this form of plasticity. We also know that we can elicit LTP using 
electrical stimulation protocols in hippocampus. Hence, we will identify LTP paradigms 
that are BDNF dependent and independent to probe for the role of eCBs. Taken together, 
studying the layer- and area-specific effects of BDNF and eCB signaling may provide 
insights in understanding activity-dependent synaptic plasticity in physiological 
conditions and in disease states.  
 
4.5 BDNF and eCB signaling at hippocampal inhibitory synapses  
4.5.1 Experimental controls 
     Since muscarinic receptor activation has been shown to selectively depolarize 
interneurons, we applied carbachol (CCh) to increase the firing of interneurons. In 
particular, CCh increases action potential firing in a subset of interneurons that generate 
large amplitude synaptic currents with fast rise time (Lemtiri-Chlieh and Levine, 2010). 
BDNF (0.8 nM) application in the presence of CCh causes a significant decrease in mean 
sIPSC frequency and in mean sIPSC amplitude. The cumulative distribution of sIPSC 
amplitude suggests that the BDNF caused a decrease in both miniature events and in 
action-potential dependent events. The shift in amplitude causes a corresponding 
decrease in sIPSC frequency. As sIPSC amplitude and frequency are dependent on 
each other, we use charge as a parameter to determine the effects of drugs tested in the 
study. Charge is defined as the quantal area per unit time and accounts for changes in 
both amplitude and frequency. Further, note that one subset of interneurons that can be 
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activated by CCh is CCK-positive basket cells (and presumably expressing CB1) and it 
has been shown that CCh can also stimulate the release of eCBs. However, we have 
shown that CCh is not required for BDNF-evoked eCB release since we have obtained 
similar results for BDNF effects on evoked responses in the absence of CCh (Lemtiri-
Chlieh and Levine, 2010).  
 
     Prior to these studies, our lab established the selective involvement of CB1Rs in the 
effect of BDNF with a series of control experiments. We examined the potential role of 
TRPV1 receptors as SR141716A can antagonize TRPV1 receptors as well. However, 
the TRPV1 receptor antagonist capsazepine had no effect on BDNF-induced 
suppression of eIPSC amplitude confirming the specific involvement of CB1 receptors. 
We have also confirmed that intracellular calcium is required by BDNF to exert its effect 
on GABA release (Lemtiri-Chlieh and Levine, 2010). We used K252a, a Trk tyrosine 
kinase antagonist as well as ANA-12, a selective TrkB receptor antagonist, to confirm 
that the effects of BDNF on spontaneous inhibitory activity are TrkB-mediated (Zhao et 
al., 2015).  
 
4.5.2. BDNF-induced eCB release at CA1 inhibitory synapses 
      BDNF can act both via pre- and postsynaptic mechanisms. Frerking and colleagues 
established in 1998 that BDNF reduces inhibitory synaptic transmission that was 
associated with presynaptic expression. However, they speculated the mechanism of 
BDNF in inhibiting neurotransmission requires a retrograde messenger (Frerking et al., 
1998). A decade later, we have identified a mechanism by which BDNF suppresses 
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GABA release by adding eCB signaling into the equation. The current study establishes 
that BDNF inhibits synaptic transmission at GABAergic synapses by inducing eCB 
release. With this study, we have extended our results from somatosensory cortex to 
hippocampal inhibitory synapses. We have, now, shown at two different brain regions, 
BDNF induces eCB release to suppress GABA release. Further studies can help us 
determine the signaling pathway required for BDNF-induced eCB release.  
 
     GABAergic interneurons have a very different developmental pattern in terms of brain 
region, transcriptional regulators and migration patterns from excitatory neurons, and 
mature GABAergic synapses show high levels of spontaneous release. However, we do 
not know if such spontaneous release is seen during developmental stages and the role 
it might play (Andreae and Burrone, 2018).  In addition, BDNF is shown to alter 
interneuron phenotype during development (Jones et al., 1994). We also do not have a 
clear understanding of how BDNF modulates GABA release in response to stimulation.  
These questions can be addressed in the future. 
 
 
4.6 Future directions of BDNF-eCB interactions at hippocampal inhibitory 
synapses 
      The current study confirms and extends our findings in layer 2/3 somatosensory 
cortex to hippocampus. Future experiments will focus on understanding the role of 
endogenous BDNF and eCBs in synaptic plasticity paradigms. One of the fundamental 
questions we will address is whether BDNF regulates eCB-mediated DSI. In the first set 
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of experiments, we will explore the role of endogenous BDNF in regulating eCB-mediated 
DSI by using the BDNF scavenger TrkB-IgG and TrkB antagonists.  In the second set of 
experiments, we will examine the effect of exogenous BDNF on eCB-mediated DSI. We 
will compare the effects of different depolarization protocols with or without added 
(exogenous) BDNF. DSI will be induced with stimulation protocols (1) in conjunction with 
0.8 nM BDNF or (2) using a theta burst stimulation paradigm (TBS) that has been shown 
to induce endogenous release of BDNF (Zhao et al., 2015). This set of studies will 
examine the effect of exogenous BDNF on eCB-mediated DSI.  
 
     Next, we want to address the role of endogenous BDNF in long term depression as 
we have identified an eCB-mediated iLTD at layer 2/3 inhibitory synapses. Finally, there 
is wealth of information available about the regulation of BDNF in LTP. We will use these 
BDNF-dependent LTP paradigms to identify the role of endocannabinoids. As mentioned 
in the introduction, BDNF can be released from pre- and postsynaptic sites and act both 
pre- and postsynaptically.  Understanding the role of eCBs in these forms of LTP will 
help us in uncovering insights regarding the sites of BDNF secretion and regulation of 
BDNF in LTP. Taken together, these studies will help us in understanding region-specific 
differences in mediating synaptic plasticity at inhibitory synapses.  
 
4.7 Conclusions 
     In summary, our understanding of eCB and BDNF function has grown tremendously 
in the last two decades, although BDNF-eCB interactions is still a growing field. The 
current work adds to the accumulating evidence of BDNF-eCB interactions in the brain. 
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We have examined both inhibitory and excitatory synapses to understand the 
physiological relevance of these interactions. We used cortical layer 5 pyramidal neurons 
as a model to study excitatory synapses and CA1 pyramidal neurons of hippocampus as 
a model to study inhibitory synapses. In future, we will extend these findings to CA3 and 
DG of hippocampus.  Understanding short- and long- term synaptic plasticity in these 
region- and layer- specific patterns will play a significant role in shaping synaptic plasticity 
and neural circuits. With the studies presented in this dissertation, I hope to shed some 
light towards future studies of synaptic plasticity mediated by either BDNF or eCBs.  
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